Initial Aβ seeds as therapeutic target for Alzheimer’s disease by Schelle, Juliane
 Initial Aβ seeds as therapeutic target for    
Alzheimer’s disease 
 
 
 
Dissertation  
 
zur Erlangung des Grades eines 
Doktors der Naturwissenschaften 
 
der Mathematisch-Naturwissenschaftlichen Fakultät  
und  
der Medizinischen Fakultät 
der Eberhard-Karls-Universität Tübingen 
 
 
 
vorgelegt  
von 
 
 
Juliane Schelle 
aus Berlin, Deutschland 
 
 
 
June 2017  
	   II	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag der mündlichen Prüfung: 21.09.2017 
 
Dekan der Math.-Nat. Fakultät:   Prof. Dr. W. Rosenstiel  
Dekan der Medizinischen Fakultät:   Prof. Dr. I. B. Autenrieth 
 
1. Berichterstatter:     Prof. Dr. M. Jucker 
2. Berichterstatter:     Prof. Dr. P. Heutink 
 
Prüfungskommission:    Prof. Dr. M. Jucker 
      Prof. Dr. P. Heutink 
      Dr. J. Neher  
Dr. D. David 
	   III	  
 
 
 
 
 
 
 
 
 
Erklärung 
 
 
Ich erkläre, dass ich die zur Promotion eingereichte Arbeit mit dem Titel:  
 
“Initial Aβ seeds as therapeutic target for Alzheimer’s disease” 
 
selbständig verfasst, nur die angegebenen Quellen und Hilfsmittel benutzt und wörtlich oder 
inhaltlich übernommene Stellen als solche gekennzeichnet habe. Ich versichere an Eides statt, 
dass diese Angaben wahr sind und dass ich nichts verschwiegen habe. Mir ist bekannt, dass 
die falsche Angabe einer Versicherung des Eides statt mit Freiheitsstrafe bis zu drei Jahren 
oder mit Geldstrafe bestraft wird. 
 
Tübingen, 30.09.2017      
 ............…….…………................. 
Unterschrift 
 
	   IV	  
 
 
 
 
Für meine Familie, Freunde und Hansi 
 
 
 
 
 
 
 
 
 
 
 
"Erinnerung ist das Seil, ... das mich herauszieht aus dem Abgrund des Nicht-Seins." 
"Auf der Suche nach der verlorenen Zeit" von Marcel Proust 
 
 
 
 
 
	   V	  
Acknowledgements 
First of all I want to thank Franziska Langer, who presented a poster during a lab visit, when 
I was applying for the Master program in Tübingen. Because of her my decision to study in 
Tübingen was enforced and I knew I would like to perform my master thesis in this lab. 
Mathias as my supervisor gave me the chance to do so two years later. I’m very grateful he 
prolonged my contract in order for me to start a PhD in his lab, during which he fully 
supported my project and me. Furthermore I want to express my gratitude to my Advisory 
Board members, Della David and Peter Heutink.  
Throughout those years as a PhD student many people influenced my carrier, my work, my 
personality, but also my private life. Thanks to Sarah for supervising and introducing me into 
the complex topic at the beginning. Ulli, Jörg, Matthias Staufenbiel, Jonas, and the entire 
Jucker lab provided help when it came to stainings, mice, strange results or whatsoever. A 
big thank you goes to Marius, Lisa, and Stephan I spent a lot of time with discussing how to 
interpret MSD results. It is mainly Timo, Jay, Manuel, Anika, Renata, Angelos, Ann-
Christin, and Mehtap I had the most fun with. I will never forget the bruises after paintball, 
the excitement during gocarting, skiing, or in Europapark, the bowling sessions, the funny 
nights at Chez Michel, the crazy Wasen experiences, and all the other great moments. In 
particular, thanks Timo for your technical help and the “Schweigefuchs” in San Diego; 
thanks Jay for your nice dance moves; thanks Manuel for unforgettable trips to Basel, 
Lausanne, and Strasbourg; thanks Anika for funny jokes; and the biggest thank you goes to 
Renata, Angelos, Ann-Christin, and Mehtap, who always had to deal with my emotions, 
doubts, anger, and tears. Thank you for always being at my side no matter if for laughing or 
crying! 
Of course without my entire family and all of my friends this PhD would not have been 
possible. However, I want to emphasize my mum, who is the one person in the whole world, 
who always understands me, gives advise, and motivates me. Sorry, for all the work stories 
you had to listen to. I really appreciate it! Svenja, thank you for supporting me and being my 
best friend. A final thank you goes to the person, who has managed to make me forget my 
PhD and all the work, the person who can make me smile no matter what, and the person I 
love truthfully. Thank you for being you, Hansi! 
	   VI	  
Table of contents 
1. Summary 1 
2. Synopsis 3 
     2.1 Alzheimer's disease at a glance 3 
           2.1.1 Characteristics of Alzheimer’s disease 3 
           2.1.2 Aggregation of the Aβ peptide as key trigger of Alzheimer's disease 8 
     2.2 Inhibiting BACE1 to impede amyloid pathology 12 
          2.2.1 Treatment strategies for Alzheimer's disease       12 
          2.2.2 Necessity of early biomarkers to detect and monitor pathological changes 18 
      2.3 Longevity of Aβ seeds and their therapeutic potential       22 
          2.3.1 Prion-like properties of aggregated Aβ      22 
          2.3.2 Stability and durability of Aβ seeds 25 
      2.4 Targeting initial Aβ seeds for the prevention of Alzheimer's disease 28 
          2.4.1 Clinical trials for Alzheimer's disease and possible reasons for recent failures 28 
          2.4.2 Delay of cerebral β-amyloidosis by short and early combination therapy 32 
      2.5 Concluding remarks and outlook    34 
      2.6 References   36 
3. Publications 55 
      3.1 Description of personal contribution 55 
      3.2 Prevention of tau increase in cerebrospinal fluid of APP transgenic mice 
            suggests downstream effect of BACE1 inhibition 56 
      3.3 Persistance of Aβ seeds in APP null mouse brain    66 
      3.4 Prevention of cerebral β-amyloidosis by targeting initial Aβ seeds    74 
4. Appendix 96 
      4.1 Abbreviations 96 
      4.2 Curriculum vitae 99 
      4.3 Bibliography 100 
	   1	  
1. Summary 
Alzheimer’s disease (AD) is the leading form of dementia interfering with daily life due to 
progressive memory loss and cognitive disabilities. With more than 45 million people 
suffering from dementia worldwide, AD is one of the costliest health conditions to society. 
Because of an increasing proportion of elderly people the number of individuals living with 
dementia is expected to more than triple by 2050. Although there are symptomatic treatments 
available that temporarily slow the worsening of clinical symptoms, a disease-modifying cure 
is still missing. Therefore, dementia, and AD in particular, is becoming a public health 
priority evoking worldwide efforts to delay or even prevent the disease from ever developing. 
The amyloid cascade hypothesis explained in detail in chapter one of this thesis proposes that 
an impaired homeostasis of production and clearance of the amyloid-β (Aβ) peptide is the 
trigger initiating a sequence of pathogenic events causing AD. Aβ misfolding and 
aggregation leads to the accumulation of cerebral amyloid plaques, a typical hallmark of AD. 
As the pathology progresses, plaques continue to develop and grow, which is suggested to 
lead to the second disease characteristic, neurofibrillary tangles (NFTs), consisting of 
hyperphosphorylated tau proteins. Aβ as the driving force of this pathological cascade has 
been regarded as the most reasonable therapeutic target. 
Therefore the second chapter is dedicated to different therapeutic approaches for AD with 
particular focus on the β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1), 
which is responsible for regulating the production of Aβ. To this end APP transgenic (tg) 
mice that mimic β-amyloidosis-related features of AD were treated with a potent BACE 
inhibitor for six months. In response to this long-term therapy, brain Aβ as well as plaque 
deposition were reduced to levels comparable to six months younger animals. Surprisingly, 
BACE inhibition also exhibited downstream effects preventing the pathology-dependent 
increase of tau in the cerebrospinal fluid (CSF). Thus, BACE inhibitors are valuable 
therapeutic agents and their effectiveness can be predicted by CSF tau measurements in 
clinical trials. These findings have been published in Alzheimer’s & Dementia: The Journal 
of the Alzheimer’s Association (Schelle et al., 2017, Alzheimer’s & Dementia: The Journal of 
the Alzheimer’s Association, 13(6), pp.701-709). 
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The third part of this thesis investigated the stability of small Aβ aggregates (Aβ seeds), 
which share pathogenic properties with the prion protein implicated in transmissible 
spongiform encephalopathies. Whereas in Aβ seeds inoculated APP tg mice the presence of 
host-derived Aβ together with the exogenously applied seeds induced their propagation, the 
injected material was undetectable in App null mice 30 days post inoculation. However, 
reinoculation with brain extracts from App null mice inoculated with Aβ seeds up to six 
months harboring Aβ levels below detection, still induced cerebral β-amyloidosis in APP tg 
hosts. In conclusion, Aβ seeds can persist even in the absence of host Aβ and regain their 
pathogenic activity as soon as sufficient Aβ becomes available. This discovery indicates on 
the one hand that lowering Aβ production inhibits the formation of new Aβ seeds and on the 
other hand that therapeutic intervention is most effective when applied at early stages. These 
results have been published in Nature Neuroscience (Ye, Fritschi, Schelle et al., 2015, Nature 
neuroscience, 18(11), pp.1559-61). 
Recent biomarker studies in familial AD subjects, which revealed that first pathological 
changes occur up to 25 years before clinical disease onset, supported this idea. Therefore, in 
the last part, pre-depositing APP tg mice were treated with a combinational therapy based on 
anti-Aβ immunization to remove Aβ seeds and a BACE inhibitor to block the production of 
soluble Aβ. Using two different APP tg mouse models results revealed that brain Aβ levels 
and plaque formation were reduced acutely after the treatment. Moreover, this short but early 
intervention delayed amyloid pathology after discontinuation of the treatment. Thus, targeting 
initial Aβ seeds by anti-Aβ combination therapy might be the most promising strategy to 
effectively prevent cerebral β-amyloidosis. These findings are now prepared for publication 
(Schelle et al., 2017). 
In summary, this doctoral thesis highlights the importance of early therapeutic intervention 
with anti-Aβ drugs in order to prevent AD. Previous studies have shown that treatment of AD 
patients who have already developed irreversible neurodegeneration might be inadequate to 
stop the progression of this devastating disorder and could be one reason to explain recent 
failures of anti-amyloid agents in numerous clinical trials. The results presented in this 
doctoral thesis indicate that the treatment focus should be shifted toward earlier stages of AD 
and even toward primary prevention before symptom onset targeting initial Aβ seeds. 
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2. Synopsis 
2.1 Alzheimer's disease at a glance     
2.1.1 Characteristics of Alzheimer’s disease 
 
26.11.1901:  Alois Alzheimer im Gespräch mit Auguste D. 
„Wie heißen Sie?“ – „Auguste.“ 
„Familienname?“ – „Auguste.“ 
„Wie heißt ihr Mann?“ – „Ich glaube Auguste.“ 
„Ihr Mann?“ – „Ach so, mein Mann.“ 
„Sind Sie verheiratet?“ – „Zu Auguste.“ 
„Frau D.?“ – „Ja, zu Auguste D.“ 
 
03.11.1906:  Tübinger Chronik und Steinlach Bote  
       Amts- und Anzeigeblatt für den Oberamts-Bezirk Tübingen.  
„Am Samstag Nachmittag 3 Uhr begannen im Hörsaale der hiesigen psychiatrischen Klinik die Verhandlungen 
der 37. Versammlung der süddeutschen Irrenärzte, zu welcher sich etwa 90 Teilnehmer eingefunden hatten... 
Über einen eigenartigen schweren Krankheitsprozess, der einen bedeutenden Schwund der Nervenzellen 
innerhalb von 4  1 2 Jahren verursachte, berichtete Privatdozent Dr. Alzheimer (München).“ 
 
11.01.1911:  Über eigenartige Krankheitsfälle des späten Alters. 
  Von A. Alzheimer. 
„Im Jahre 1906 habe ich einen Fall von Erkrankung des präsenilen Alters beschrieben, ... die damals noch 
unbekannt war. Hinsichtlich der klinischen Erscheinung war eigenartig eine rasch sich entwickelnde und in 
kurzer Zeit zu den tiefsten Graden fortschreitende Verblödung...“ 
 
Already in 1901 the neuropathologist Alois Alzheimer started to investigate his patient 
Auguste Deter, who suffered from a rapid loss of memory, disorientation in time and space, 
auditory hallucinations, and psychosocial impairment. Because she was only 56 years old 
when she died, she did not meet the inclusion criteria for senile dementia that had been 
known so far. Hence, senile dementia was excluded as a reason for her symptoms 
(Alzheimer, 1907). That is why in 1906 at a conference in Tübingen Alzheimer described, 
and published in 1907 and 1911, an unusual illness of the cerebral cortex, with unfamiliar 
clinical as well as pathological characteristics (Alzheimer, 1907; Alzheimer, 1911). 
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Nowadays Alzheimer’s disease (AD) - named after the discoverer - is the most common 
neurodegenerative disease and the leading cause of dementia worldwide (Dartigues, 2009; 
Holtzman et al., 2011). Dementia is a general term for conditions characterized by a decline 
in memory or other cognitive skills due to neuronal loss leading to a person’s inability to 
perform everyday activities (Alzheimer’s Association, 2014). AD specifically is 
characterized by a progressive loss of episodic memory impeding recollection of recent 
events and activities, disorientation to time and place, and later the decline in executive 
functions, language, and emotional stability (Petersen et al., 1999; Alzheimer’s Association, 
2014). The global number of AD cases is estimated at 46.8 million with a new case of 
dementia arising somewhere in the world every four seconds (World Alzheimer Report, 
2015). As life expectancy keeps rising and with increasing age being the greatest known risk 
factor for AD, the number of patients is expected to triple by 2050 (Reitz et al., 2011; Wimo, 
2015; World Alzheimer Report, 2015). In fact, AD is not only a burden for the ever-
increasing number of new patients worldwide, but has also tremendous consequences for 
their relatives, caregivers, as well as society (World Alzheimer Report, 2015). The global 
costs of dementia have increased by more than 35% between 2010 and 2015 and will soon 
escalate into a trillion dollar economic challenge (World Alzheimer Report, 2015). Therefore 
AD risk reduction, prevention, care, and cure should be made a public health priority. 
Already more than 100 years ago, Alois Alzheimer microscopically and histologically 
analyzed Auguste Deter’s brain post-mortem and reported two cardinal pathological 
alterations, namely extracellular plaques and bundles of neurofibrils (Alzheimer, 1911). Both 
hallmark lesions still remain a valid and definite clinical diagnosis for AD (Scheltens et al., 
2016). The constituents of these plaques are aggregated forms of a small peptide named 
amyloid-β (Aβ), which forms fibrillar deposits (Glenner & Wong, 1984; Masters et al., 1985; 
Duyckaerts et al., 2009, Holtzman et al., 2011). Neurofibrillary tangles (NFTs) composed of 
abnormally hyperphosphorylated tau, a microtubule-associated protein, are found inside 
nerve cell bodies (dystrophic neurites) (Kosik et al., 1986, Grundke-Iqbal et al., 1986; 
Goedert et al., 1988; Goedert & Spillantini, 2006; Mandelkow & Mandelkow, 2012). 
Increased numbers of brain region-specific Aβ aggregates as well as NFTs are suggested to 
lead to the progression of AD (Braak & Braak, 1991; Thal et al., 2002; Jucker & Walker, 
2013). Both assemblies show features characteristic of amyloid (Glenner & Wong, 1984; 
Masters et al., 1985; Duyckaerts et al., 2009; Eisenberg & Jucker, 2012). Amyloids are 
predominantly composed of β-sheet structures displaying a specific cross-β fiber diffraction 
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pattern. Furthermore they bind to the dye Congo Red, which exhibits anomalous colors, 
referred to as apple green birefringence, when examined between crossed-polarizers 
(Rambaran & Serpell, 2008; Sipe et al., 2014). Amyloids are usually unbranched and fibrillar 
in structure giving rise to toxic tissue deposits (Haass & Selkoe, 2007; Eisenberg & Jucker, 
2012; Klein, 2013).  
In 1992, John Hardy and Gerald Higgins described the most dominant model of AD 
pathogenesis to date. This amyloid cascade hypothesis postulates that an imbalance between 
the production and/or the clearance of Aβ peptides due to altered expression or processing of 
the β-amyloid precursor protein (APP) causes the deposition of Aβ in plaques followed by a 
sequence of pathogenic events leading to AD dementia (Hardy & Higgins, 1992; Hardy & 
Selkoe, 2002).  
Aβ is produced by proteolytic cleavage of APP, a transmembrane protein with a single 
membrane-spanning domain (Glenner & Wong, 1984; Masters et al., 1985; Kang et al., 
1987). Alternative splicing gives rise to different APP isoforms: APP695 is predominantly 
expressed in the central nervous system (CNS), whereas APP751 and APP770 are ubiquitously 
expressed in non-neuronal tissue (Kitaguchi et al., 1988; Ponte et al., 1988; Tanaka et al., 
1988). Despite the involvement of APP in synaptic functioning and transmission as well as 
plasticity and memory formation, its exact physiological role is still under debate (Dawkins 
& Small, 2014). However, cerebral APP695 cleavage and processing can be divided into a 
non-amyloidogenic (non-pathogenic) and an amyloidogenic (pathogenic) pathway, both of 
which are illustrated in Figure 1. The non-amyloidogenic pathway is characterized by APP 
cleavage within the Aβ region by α-secretase and sequentially γ-secretase. This processing 
precludes the formation of the Aβ peptide and thereby interferes with amyloid deposition. 
The α-secretase belongs to the disintegrin and metalloprotease (ADAM) family (Sisodia, 
1992; Lammich et al., 1999) and its APP cleavage releases soluble APP-α (sAPPα) externally 
from the endosome or cell membrane (Ghiso et al., 1989; Kojro & Fahrenholz, 2005; Jorissen 
et al., 2010). The remaining membrane-bound C-terminal fragment of 83 amino acid residues 
(C83 or CTFα) is subsequently cleaved by the γ-secretase. Two short non-amyloidogenic 
fragments termed p3 and APP intracellular domain (AICD) are produced (Haass & Selkoe, 
1993). The γ-secretase is a multiprotein complex with its key biochemical components 
presenilin 1 (PS1) or presenilin 2 (PS2), glycosylated nicastrin (NCT), anterior pharynx-
defective phenotype 1 (Aph-1), and presenilin enhancer 2 (Pen-2) (De Strooper, 2003; 
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Edbauer et al., 2003). Presenilins are aspartyl proteases and build the active site of the 
enzyme (De Strooper et al., 1998; Wolfe et al., 1999).  
The amyloidogenic pathway is an alternative APP cleavage pathway resulting in 
Aβ generation. The β-site APP cleaving enzyme 1 (BACE1, β-secretase) initially cleaves 
APP at a position located 99 amino acids from the C-terminus (N-terminus of Aβ) (Vassar et 
al., 1999). Its highly sequence-specific cleavage results in the release of soluble APP-β 
(sAPPβ) into the extracellular space (Selkoe, 1991). BACE1 is a membrane-bound aspartyl 
protease (Vassar & Citron, 2000; Cole & Vassar, 2007, Dislich & Lichtenthaler, 2012) 
present in acidic cellular compartments like the Golgi apparatus and endosomes (Vassar et 
al., 1999). Other BACE1 substrates are important for the formation of voltage gated sodium 
channels and axon myelination (Wong et al., 2005; Hu et al., 2006). The remaining 
hydrophobic, membrane-spanning C-terminal region of APP consisting of 99 amino acid 
residues (known as C99 or CTFβ) becomes a substrate for the γ-secretase (Vassar et al., 
1999; Haass et al., 2012). In contrast to the non-amyloidogenic pathway, the γ-secretase 
liberates AICD into the cytosol. In addition, various Aβ species are released into the 
extracellular space through progressive γ-secretase cleavage steps (between residues 37 and 
43) (Vassar et al., 1999; Haass et al., 2012) after initially releasing Aβ48 or Aβ49 as two major 
precursors (Takami et al., 2009). The predominant Aβ species in healthy individuals is a 
peptide of 40 amino acid residues in length (Aβ40) (De Strooper & Annaert, 2010), in contrast 
to the less abundant (approximately 10%) but more hydrophobic and presumably pathogenic 
42 residue variant (Aβ42) (Bitan et al., 2003; Yan & Wang, 2006). Consistently, longer 
Aβ species are more prone to aggregate than shorter ones (Burdick et al., 1992; Qi-Takahara 
et al., 2005). Because Aβ42 fosters oligomerization, fibrillization, and plaque deposition, it is 
more amyloidogenic and neurotoxic than Aβ40 (Jarrett et al., 1993; Suzuki et al., 1994; 
Younkin, 1998; Bitan et al., 2003). Furthermore AD patients often exhibit an increased 
Aβ42:40 ratio enhancing synaptotoxicity and amyloid aggregation (Pauwels et al., 2012). 
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Figure 1: Sequential cleavage of the amyloid precursor protein (APP) and potential consequences of 
amyloid β (Aβ) peptide aggregation. During the non-amyloidogenic pathway APP is processed by the α-
secretase giving rise to the membrane-bound C-terminal fragment C-83 and the soluble APPα (sAPPα). 
Sequential cleavage by the γ-secretase liberates p3 into the extracellular space and the APP intracellular domain 
(AICD). In contrast, the amyloidogenic pathway produces soluble APPβ (sAPPβ) and C-99 in response to β-
secretase cleavage. The latter is further processed by the γ-secretase resulting in the release of AICD and 
extracellular Aβ molecules. According to the amyloid cascade hypothesis Aβ aggregation is suggested to trigger 
a sequence of major pathogenic events leading to dementia associated with Alzheimer’s disease. However, 
Alzheimer’s pathogenesis  probably comprises parallel and circular interactions of risk factors rather than a 
linear pathological process (modified from Dislich & Lichtenthaler, 2012 and Hardy & Selkoe, 2002). 
Recently a novel cleavage site at amino acid 504-505 of APP695 was discovered called η-
cleavage (Willem et al., 2015). A membrane-bound matrix metalloproteinase, the η-secretase, 
cleaves APP and releases CTF-η and Aη of various sizes after further processing by α- or β-
secretase (Willem et al., 2015). Although accumulations of the η-secretase and CTF-η found 
within dystrophic neurites might contribute to AD pathogenesis (Willem et al., 2015), AD 
causing mutations all affect Aβ, and not Aη, production and aggregation (Bekris et al., 2010), 
which will be described in more detail in the next chapter. 
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According to the amyloid hypothesis, aggregation of Aβ in brain regions responsible for 
memory and cognition is followed by the formation of intracellular NFTs (Kosik et al., 1986; 
Goedert & Spillantini, 2006) and many other structural and functional changes (Duyckaerts et 
al., 2009; Holtzman et al., 2011; Nelson et al., 2012). Those include aberrant neuronal 
network activities due to impaired synaptic function (Dekosky & Scheff, 1990), neuronal loss 
leading to brain atrophy (Jobst et al., 1994), and neuroinflammation accompanied by 
oxidative stress and thereby activation of astrocytes and microglia, the immune cells of the 
brain (Brun & Englund, 1981;  Prinz & Mildner, 2011; Prokop et al., 2013). Many recent 
evidences have highlighted especially the immune system as a key influencer in increasing 
AD risk and accelerating AD progression (Naj et al., 2011; Jonsson et al., 2013; Huang et al., 
2017). However, rather than a linear sequence of pathological events, multicausal, circular, 
and parallel pathways and risk factors lead to the manifestation of dementia. Nevertheless, all 
mentioned processes within this pathogenic cascade contribute to the progression of the pre-
clinical/prodromal phase of AD to mild cognitive impairment (MCI), followed by the 
manifestation of mild (early stage), then moderate (middle stage), and finally severe (late 
stage) AD dementia (Chertkow et al., 2013). 
 
2.1.2 Aggregation of the Aβ peptide as key trigger of Alzheimer’s disease 
The most convincing piece of evidence supporting the amyloid cascade hypothesis and the 
key role for Aβ deposition as the initiative event in AD pathogenesis comes from human 
genetic studies. AD can be divided into an early-onset (< 60 years) familial form (EOAD) 
and a late-onset (> 60 years) sporadic form (LOAD). Only less than one percent of AD 
patients carry a dominantly autosomal inherited mutation causing early-onset familial AD 
(FAD) (Bekris et al., 2010). In fact, all of those missense mutations cause dysfunctional Aβ 
homeostasis and occur in proteins involved in the generation of Aβ (Hardy & Selkoe, 2002; 
Selkoe & Hardy, 2016). On the other hand, mutations in the microtubule associated protein 
tau (MAPT) gene do not cause AD but frontotemporal dementia, parkinsonism linked to 
chromosome 17 (FTDP-17), progressive supranuclear palsy, and other tauopathies (Pagon et 
al., 1993; Goedert & Jakes, 2005).  
Specific App gene mutations within and immediately flanking the Aβ region were identified 
in families suffering from EOAD such as those carrying the Dutch mutation (E693Q) (Van 
Broeckhoven et al., 1990), the London mutation (V171I) (Goate et al., 1991), the Indiana 
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mutation (V717F) (Murrell et al., 1991), the Swedish double mutation (K670N/M671L) 
(Mullan et al., 1992), and the Arctic mutation (E693G) (Kamino et al., 1992), named after the 
region of discovery. All these App mutations increase Aβ production or change the relative 
amount of the amyloidogenic Aβ42 versus Aβ40 peptide (Citron et al., 1992; Suzuki et al., 
1994). Hence, Aβ aggregates and insoluble parenchymal plaques and/or cerebral hemorrhage 
with amyloidosis develop and affect normal brain functioning (Herzig et al., 2004; Goedert & 
Spillantini, 2006). In rare individuals, the App gene is duplicated, which also causes EOAD 
(Rovelet-Lecrux et al., 2006; Sleegers et al., 2006). Due to the App gene being located on 
chromosome 21 (Goldgaber et al., 1987; Robakis et al., 1987), Down’s syndrome (trisomy of 
chromosome 21 and therefore also of the App gene) patients develop typical AD 
neuropathology because they produce excessive amounts of Aβ lifelong (Masters et al., 1985; 
Lemere et al. 1996). Moreover, amino acid substitutions in the presenilin 1 (PSEN1) or 2 
(PSEN2) genes cause the most common and most aggressive form of EOAD due to the 
relative elevation of Aβ42 levels in the brain, which leads to profound Aβ deposition in mid-
life (Jarrett et al., 1993; Borchelt et al., 1996; Citron et al., 1997; Selkoe, 2001). In contrast, 
an App missense mutation (A673T) at the second amino acid of the Aβ region has been 
identified precipitating a reduced Aβ production due to decreased APP cleavage by BACE1 
(Jonsson et al., 2012). Consequently, not only the aggregation potency of this mutant Aβ 
form is lowered but mutation-carriers also have significantly decreased plasma Aβ and 
therefore the risk of developing AD is reduced (Jonsson et al., 2012; Benilova et al., 2014; 
Maloney et al., 2014; Zheng et al., 2015; Martiskainen et al., 2017), which confirms the 
critical involvement of Aβ in AD pathogenesis. 
In contrast to the small proportion of FAD patients, in which one specific mutation causes the 
disease, the majority of cases manifest as the sporadic form, where many genetic and 
environmental factors could contribute to the disorder (Alzheimer Association Report, 2014). 
Although the causative triggers of the common sporadic form of AD are still unknown, 
genome-wide association studies (GWAS) and recent investigations about epigenetic 
mechanisms revealed certain risk factors (Reitz et al., 2011; Bettens et al., 2013). The 
strongest risk factor for developing LOAD is advanced age. Nevertheless, aging alone is not 
sufficient to cause the disease (Reitz et al., 2011). An increased risk of developing AD is the 
inheritance of one (fourfold increased risk) or two (twelvefold increased risk) copies of the 
APOE ε4 gene encoding for the ε4 form (APOE4) of the apolipoprotein E (APOE) 
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(Schmechel et al., 1993; Strittmatter et al., 1993; Saunders et al., 1993; Corder et al., 1993; 
Raber et al., 2004). The APOE4 protein leads to chronically decreased brain clearance of Aβ, 
more amyloid deposits, and thereby contributes to AD risk (Rebeck et al., 1993; Holtzman et 
al., 2000; Castellano et al., 2011). Other risk genes for LOAD include ABCA7 (ATP-binding 
cassette sub-family A member 7) involved in Aβ clearance (Hollingworth et al., 2011; Kim et 
al., 2013) and SORL1 (sortilin-related receptor 1) (Rogaeva et al., 2007), BIN1 (bridging 
integrator protein 1) (Seshadri et al., 2010), and PICALM (phosphatidylinositol-binding 
clathrin assembly protein) (Harold et al., 2009) as regulators of endosomal vesicle recycling 
and Aβ transportation. Furthermore CR1 (complement receptor 1) (Lambert et al., 2009), 
CD33 (member of the sialic-acid-binding immunoglobulin-like lectins family) (Bertram et 
al., 2008; Naj et al., 2011), and TREM2 (triggering receptor expressed on myeloid cells 2) 
(Jonsson et al., 2013; Wang et al., 2015b), all involved in the phagocytic immune response to 
Aβ deposition, are other identified risk loci. Recently, a protective allele with reduced SPI1 
(spi-1 proto-oncogene) expression and therefore reduced AD risk was discovered (Huang et 
al., 2017). SPI1 encodes for the microglial transcription factor PU.1, which was found to 
regulate many established AD risk genes, indicating a crucial role of microglia in the 
pathogenesis of AD (Huang et al., 2017). In addition to those genetic AD risk factors, 
smoking (Anstey et al., 2007; Rusanen et al., 2010), obesity (Kivipelto et al., 2005; Whitmer 
et al., 2008; Luchsinger et al., 2012), type 2 diabetes (Ahtiluoto et al., 2010; Cheng et al., 
2011), low education (Stern et al., 1994), traumatic brain injury (Mortimer et al., 1991; 
Schofield et al., 1997; Lye & Shores, 2000), and other factors have been associated with an 
increased likelihood of developing AD.  
In addition to the detailed analyses of different familial and sporadic AD cases that support 
the amyloid hypothesis (Citron et al., 1992; Cai et al., 1993; Suzuki et al., 1994; Hardy et al., 
1998; Reitz et al., 2011), genetically modified rodents overexpressing mutant forms of human 
APP or presenilin were generated in order to partly mimic distinct features of AD pathology 
(Games et al., 1995; Hsiao et al., 1996; Sturchler-Pierrat et al., 1997; Lewis et al., 2001; 
Radde et al., 2006; Drummond & Wisniewski, 2017). Notably, wild type (wt) mice do not 
manifest any neuropathological signs of AD. This might be due to their short lifespans, 
missing or altered cofactors, environmental circumstances, or the three amino acids of the Aβ 
sequence that differ between mice and humans (Yamada et al., 1987; Walker & Jucker, 
2017). Although APP transgenic (tg) mice do not express the entire AD pathology by lacking 
NFTs and extensive neuronal loss (Calhoun et al., 1998; Rupp et al., 2011), they recapitulate 
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age-related cerebral β-amyloidosis in the brain including parenchymal plaques and vascular 
deposition very similar to Aβ lesions characteristic for AD (Ashe & Zahs, 2010; Jucker, 
2010). For example, APP23 tg mice overexpress the K670M/N671L-mutated human APP 
(APPSwedish) and start to form detectable Aβ deposits at six to eight months of age 
(Sturchler-Pierrat et al., 1997). APPPS1 tg mice co-express in addition to APPSwedish 
human mutated presenilin, which leads to the development of the first Aβ plaques after six 
weeks of age (Radde et al., 2006). Another tg mouse model that mimics at least partially 
sporadic AD overexpresses human wt APP (APP51 mice) and exhibits a much later onset of 
Aβ deposition (Bodendorf et al., 2002).  
Two findings that might undercut the amyloid hypothesis of AD are the presence of Aβ 
plaques in some aged individuals without cognitive deficits (Braak & Braak, 1991), in line 
with the poor correlation of the Aβ load with the degree of clinical symptoms (Arriagada et 
al., 1992; Foley et al., 2015). In fact, the quantity of NFTs seems to correlate much better 
with cognitive impairment than plaque burden (Giannakopoulos et al., 2003). This potential 
discrepancy suggests that Aβ is not directly responsible for disease progression. Other causal 
contributions of Aβ to AD could be on the one hand that Aβ has to reach a certain threshold 
to cause pathogenic events or on the other hand that Aβ is the trigger of the disease process, 
which then becomes rather independent of Aβ (Karran et al., 2011). In one way or the other, 
Aβ aggregation is an early event that leads to downstream cellular and molecular brain 
alterations such as tangle formation, which then result in neuronal dysfunction and at a final 
stage in dementia (Selkoe & Hardy, 2016). Recent fluid and imaging biomarker studies in 
FAD patients, explained in more detail in chapter 2.2.2, revealed that Aβ changes occur 
before tau increases in the cerebrospinal fluid (CSF) and precede the onset of clinical 
symptoms by decades (Jack et al., 2010; Holtzman et al., 2011b; Bateman et al., 2012). 
Therefore non-demented people, who exhibit amyloid deposits post-mortem, could have been 
on the way to develop AD. 
Taken together, human genetic as well as biomarker studies indicate that in AD pathogenesis 
Aβ accumulation is the driving force for downstream tauopathy and neurodegeneration. 
Although AD is a complex disease with multiple interactions among genetic, epigenetic, and 
environmental factors (Chouliaras et al., 2010; Barnes & Yaffe, 2011), Aβ aggregation seems 
to be the initial, underlying cause of AD and a reasonable target for therapeutic intervention. 
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2.2 Inhibiting BACE1 to impede amyloid pathology 
 
In reference to: 
Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests 
downstream effect of BACE1 inhibition 
Juliane Schelle, Lisa Häsler, Jens C. Göpfert, Thomas O. Joos, Hugo Vanderstichele, Erik 
Stoops, Eva-Maria Mandelkow, Ulf Neumann, Derya R. Shimshek, Matthias Staufenbiel, 
Mathias Jucker, Stephan A. Kaeser (2017). Alzheimer’s & Dementia: The Journal of the 
Alzheimer’s Association, 13(6), pp.701-709.  
 
2.2.1 Treatment strategies for Alzheimer’s disease 
Current Food and Drug Administration (FDA) approved AD treatments focus only on the 
amelioration of symptoms rather then the prevention or slowdown of disease progression. 
Currently, AD patients undergo symptomatic therapies with acetylcholinesterase-inhibitors 
and a glutamate antagonist. Because the neurotransmitter acetylcholine (ACh) involved in 
learning and memory (Mitsushima et al., 2013) is depleted in AD brains (Davies & Maloney, 
1976; Perry et al., 1977) and even interacts with Aβ directly (Garcia-Osta & Alberini, 2009; 
Puzzo et al., 2015), Rivastigmine, Donepezil, and Galantamine provide symptomatic relief 
due to inhibition of ACh clearance by the acetylcholinesterase (Román & Kalaria, 2006; 
Anand & Singh, 2013; Godyn et al., 2016). However, only a minority of treated patients 
shows modest and transient improvement of cognitive functions. Furthermore the utility of 
each of these drugs is limited because they are only effective in earlier pre-dementia stages 
by allowing the retention of ACh (Hansen et al., 2008). Another approved drug is 
Memantine, an uncompetitive N-methyl-D-aspartate (NMDA)-type glutamate receptor 
antagonist (Winblad & Poritis, 1999; Chu, 2012). Decreased glutamate uptake from 
microglia cells can lead to glutamate-mediated excitotoxicity, which can be detrimental to 
cells (Prentice et al., 2015). Memantine prevents aberrant neuronal stimulation and shows 
symptomatic benefits in moderate to severe AD patients (Cummings, 2004). It either can be 
administered alone or in combination with an acetylcholinesterase inhibitor (Wang et al., 
2015a). Another glutamatergic agent, Riluzole, is currently in phase II for the treatment of 
AD.  
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Although the four approved drugs, summarized in Table 1, became the standard of care for 
AD patients since they slow the decline in quality of life, but they do not modify the primary 
pathological processes underlying the disease. Hence, AD’s therapy research shifted toward 
different targets namely anti-Aβ agents assuming Aβ aggregation as the initial driving force 
of the disease (Hardy & Selkoe, 2002; Golde et al., 2010). Multiple approaches targeting 
specific intermediates in the pathological pathway from Aβ monomer to amyloid deposit 
have gained scientific interest. In Table 1 the entire spectrum of therapeutic anti-Aβ agents in 
clinical trials is listed. Besides active and passive Aβ vaccinations to accelerate Aβ clearance, 
researchers focused on the β- and γ-secretase cleaving APP as therapeutic targets, especially 
after the discovery that Aβ is constantly produced and secreted by cells throughout life 
(Haass et al., 1992). Inhibitors of each enzyme should therefore decrease Aβ production and 
prevent plaque formation.  
As the γ-secretase complex consists of four different substrates, it provides many binding 
sites for selective inhibitors. Although the identity of this enzyme has been known for a long 
time, it has been difficult to develop drugs that are able to penetrate the blood-brain-barrier 
(BBB) and selectively inhibit the amyloidogenic pathway of APP processing. Moreover, the 
γ-secretase cleaves 50 other substrates apart from APP such as voltage-gated sodium channel 
subunits and Notch receptors, which regulate cell proliferation and differentiation (Kopan & 
Ilagan, 2009; Citron, 2010; De Strooper & Annaert, 2010; Golde et al., 2011; Schor, 2011). 
Their inhibition led to severe side effects in numerous studies using γ-secretase inhibitors 
from Eli Lilly & Co (Semagacestat) and Bristol-Meyers Squibb (Avagacestat) including 
gastrointestinal bleedings, immunosuppression, and skin cancer (Searfoss et al., 2003; Wong 
et al., 2004; Fleisher et al., 2008; Coric et al., 2012; Doody et al., 2013). Hence, Notch-
sparing γ-secretase modulators were designed and are currently tested in clinical trials 
because they selectively decrease the production of aggregation-prone Aβ42 in favor of 
shorter Aβ species that may be less toxic (EVP-0962, FORUM Pharmaceuticals, Inc.) (Kukar 
et al., 2008; Wolfe, 2007; Golde et al., 2011; Karran et al., 2011). Interestingly, γ-secretase 
modulators such as cholestenoic acid, a cholesterol metabolite, also exist endogenously in the 
brain and might act as viable therapeutic targets as well.  
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Table 1: Therapeutic anti-Aβ agents in Alzheimer’s disease  
Target type Name Therapy type FDA Status Company 
Cholinergic Donepezil Small molecule Approved Esai Co., Ltd., Pfizer, Inc. 
Cholinergic Galantamine Small molecule Approved 
Janssen Pharmaceutica, Ortho-
McNeil Pharmaceutical, 
Sanochemia Pharmazeutika, 
Shire PLC, Takeda 
Pharmaceutical Company 
Cholinergic Rivastigmine Small molecule Approved Novartis Pharmaceuticals 
Glutamatergic Memantine Small molecule Approved Forest Laboratories, Inc., H. Lundbeck A/S, Merz Pharma 
Glutamatergic Riluzole Small molecule Phase II Sanofi S.A. 
γ-secretase 
inhibitor EVP-0962 Small molecule Phase II FORUM Pharmaceuticals Inc. 
BACE inhibitor E2609 Small molecule Phase II Biogen, Inc., Esai Co., Ltd. 
BACE inhibitor AZD3293 Small molecule Phase III Eli Lilly & Co., AstraZeneca 
BACE inhibitor CNP520 Small molecule Phase II/III Amgen, Inc., Novartis Pharmaceuticals 
BACE inhibitor JNJ-54861911 Small molecule Phase II/III Janssen Pharmaceutica, Shionogi 
BACE inhibitor Verubecestat Small molecule Phase III Merck & Co, Inc. 
Aβ clearance AAB-003 Passive immunotherapy  Phase I 
Janssen Pharmaceutica, Pfizer, 
Inc. 
Aβ clearance Solanezumab Passive immunotherapy  Phase III Eli Lilly & Co. 
Aβ clearance Crenezumab Passive immunotherapy  Phase III Genentech, Inc. 
Aβ clearance Gantenerumab Passive immunotherapy  Phase III 
Chugai Pharmaceutical Co., 
Ltd., Hoffmann-La Roche 
Aβ clearance BAN2401 Passive immunotherapy  Phase II 
BioArtic Neuroscience AB, 
Biogen, Inc., Esai Co., Ltd. 
Aβ clearance Aducanumab Passive immunotherapy  Phase III Biogen, Inc. 
γ-secretase 
inhibitor Semagacestat Small molecule Discontinued Eli Lilly & Co. 
γ-secretase 
inhibitor Avagacestat Small molecule Discontinued Bristol-Myers Squibb 
BACE inhibitor RG7129 Small molecule Discontinued Roche 
BACE inhibitor LY2811376 Small molecule Discontinued Eli Lilly & Co. 
BACE inhibitor LY2886721 Small molecule Discontinued Eli Lilly & Co. 
Aβ clearance AN-1792 Active immunotherapy  Discontinued 
Janssen Pharmaceutica, Pfizer, 
Inc. 
Aβ clearance Bapineuzumab Passive immunotherapy  Discontinued 
Pfizer, Inc., Johnson & Johnson 
Pharmaceutical Company, 
Janssen Pharmaceutica, Elan 
Pharmaceuticals, Inc.  
Aβ clearance GSK933776 Passive immunotherapy  Discontinued GlaxoSmithKline PLC 
 
Updated summer 2017; BACE = β-site amyloid precursor protein cleaving enzyme (adapted from Graham et al., 
2017) 
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While the safe use of γ-secretase modulators is still pending, the other rate-limiting secretase 
processing APP BACE1 that is known to be elevated in AD patients became the focus of 
therapeutic approaches (Ghosh et al., 2008; Citron, 2010; De Strooper & Annaert, 2010; 
Golde et al., 2011; Kandalepas et al., 2013). Already other members of the aspartic protease 
family could be successfully inhibited such as renin and human immunodeficiency virus 
(HIV) protease-1 (Nguyen et al., 2008). BACE1 null mice overexpressing human APP lacked 
amyloid plaques (Luo et al., 2003) but showed sensorimotor impairments and spatial memory 
deficits (Kobayashi et al., 2008) mainly due to the involvement of BACE1 in the metabolism 
of myelination during development (Willem et al., 2006; Vassar et al., 2009; Hitt et al., 2010; 
Cai et al., 2012). Therefore research interest shifted more toward partial and transient BACE1 
inhibition, which was sufficient to significantly reduce Aβ deposition in APP tg mice 
(McConlogue et al., 2007; Fukumoto et al., 2010; Eketjäll et al., 2013; Neumann et al., 
2015). However, initial clinical trials turned out to be unsuccessful because of low oral 
bioavailability and low BBB penetration. Nevertheless partial BACE1 inhibition seemed to 
display less severe side effects than drugs targeting the γ-secretase. The development of more 
lipophilic compounds revealed better oral availability and good brain permeability but lacked 
high potency and accurate target selectivity for BACE1 over other enzymes such as BACE2 
(Stachel et al., 2004; Cole et al., 2006; Baxter et al., 2007). BACE2 is a closely related β-
secretase with significant structural homology compared to BACE1. In contrast to its 
homologue, BACE2 is not primarily expressed in the brain but in colon, kidney, and pancreas 
and is therefore not considered to be a major contributor to Aβ generation. For example, 
Novartis Pharmaceuticals developed a BACE inhibitor (NB-360) that was not selective for 
BACE1 but effectively reduced brain Aβ in rodents and dogs and blocked the progression of 
cerebral Aβ deposition in APP tg mice (Neumann et al., 2015). However, this potent BACE 
inhibitor induced hair depigmentation in mice suggesting that a potential therapeutic agent 
for AD should selectively target BACE1 (Shimshek et al., 2016). Ongoing phase II and III 
studies include selective small-molecule BACE1 inhibitors with satisfactory 
pharmacokinetics, including E2609 from Biogen, Inc., Eisai Co., Ltd., AZD3293 from Eli 
Lilly & Co., AstraZeneca, JNJ-54861911 from Janssen Pharmaceutica, Shionogi, 
Verubecestat from Merck & Co, Inc., and also the processed and improved compound from 
Novartis Pharmaceuticals, Amgen, Inc. called CNP520 (Godyn et al., 2016, Folch et al., 
2016).  
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Because the alpha-secretase conducts the non-amyloidogenic pathway and prevents Aβ 
production, the elevation of α-secretase cleavage seems to be a viable option for treating AD 
(Kuhn et al., 2010). Indeed, in APP tg mice overexpression of ADAM10 acting as α-secretase 
reduced plaque deposition and improved cognitive impairment (Postina 2004; Lichtenthaler, 
2011). Despite initial excitement, off-target effects of α-secretase modulators due to over 30 
different substrates of the metalloprotease besides APP as well as underlying mechanisms 
need to be identified and understood first (Edwards et al., 2008; Lichtenthaler, 2011). 
Not only the manipulation of APP processing is a rational and promising strategy to treat or 
even prevent AD but also immunological approaches enhancing Aβ clearance. Besides 
increased amyloidogenic APP processing and Aβ production, inefficient removal of Aβ 
peptides contribute to the pathology (Hardy & Selkoe 2002; Selkoe, 2001). In AD patients, 
Aβ clearance is altered due to reduced activity of Aβ-degrading enzymes such as neprilysin 
(Mawuenyega et al., 2010; Folch et al., 2016). Increasing the expression of those Aβ-
degrading enzymes would be one therapeutic strategy and was already shown to increase Aβ 
clearance in APP tg mice (Mueller-Steiner et al., 2006). However, those approaches turned 
out to be difficult to translate into clinical trials. To this end, anti-Aβ immunotherapy was 
reported as an effective amyloid clearance mechanism. Active immunization stimulates the 
immune system to produce antibodies when exposed to synthetic Aβ42 as antigen. Those 
immunization studies resulted in the clearance of Aβ plaques and improved cognitive 
performance in APP tg mice (Schenk et al., 1999; Morgan et al., 2000). However, a phase II 
clinical trial using active immunization with the full-length Aβ42, called AN-1792 (Janssen 
Pharmaceutica, Pfizer, Inc.), had to be stopped because of meningoencephalitis in 6% of 
immunized patients potentially caused by T-cell and microglia activation (Nicoll et al., 2003; 
Orgogozo et al., 2003; Holmes et al., 2008). Nevertheless, post-mortem analyses of the 
subjects enrolled in this trial revealed reduced plaque deposition in cortical brain regions 
(Nicoll et al., 2003; Nicoll et al., 2006).  
Severe side-effects caused by active immunization led to passive immunization approaches, 
in which Aβ specific antibodies are applied activating clearance mechanisms in the brain 
such as Fc-receptor-mediated phagocytosis of microglia cells and subsequent peptide 
degradation (Bard et al., 2000). Peripheral administration of humanized monoclonal Aβ 
antibodies reduced or even prevented amyloid fibril formation in vitro (Solomon et al., 1996) 
and in vivo in mice (Bard et al., 2000; Pfeifer et al., 2002; Lee et al., 2006; Fuller et al., 
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2015). Although antibodies struggle to cross the BBB, they appear to be highly specific, safe, 
and well tolerated (Graham et al., 2017). Nevertheless antibody infusion also induced 
cerebral hemorrhages at amyloid-laden vessels (Pfeifer et al., 2002) and neuronal 
hyperactivity (Busche et al., 2015). The first human studies used N-terminal Aβ antibodies, 
which induced amyloid-related imaging abnormalities (ARIA), including vasogenic edema 
and microhemorrhages in a couple of patients (Salloway et al., 2009; Sperling et al., 2011). 
For example, the N-terminal Aβ antibody GSK933776 (GlaxoSmithKline PLC) (Leyhe et al., 
2014) was discontinued due to the lack of clinical efficacy. Afterwards, antibodies with a 
more central epitope of Aβ were designed. Solanezumab (Eli Lilly & Co.) for example 
recognizes the mid-domain of Aβ, which becomes unavailable to the antibody during the 
process of Aβ aggregation, and therefore removes mainly small soluble Aβ species (Crespi et 
al., 2015). In contrast, Crenezumab (Genentech, Inc.) (Crespi et al., 2015) and Gantenerumab 
(Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche) (Bohrmann et al., 2012) recognize 
rather aggregated forms of Aβ and are currently tested in a phase II and III trial, respectively. 
In other clinical trials mild to moderate AD patients have been treated with AAB-003 (Janssen 
Pharmaceutica, Pfizer, Inc.) binding fibrillar and soluble Aβ species, whereas early AD 
subjects have been infused with the Aβ protofibril specific antibody BAN2401 (BioArtic 
Neuroscience AB, Biogen, Inc., Esai Co., Ltd.). Another anti-Aβ immunotherapeutic drug is 
the human monoclonal antibody Aducanumab (Biogen, Inc.) generated from healthy, aged 
donors. It binds a conformational epitope targeting aggregated forms of Aβ. In a phase I 
clinical trial Aducanumab decreased amyloid deposition and delayed cognitive decline in 
prodromal to mild AD patients, which is why Aducanumab is currently tested in a phase III 
trial (Sevigny et al., 2016). 
In addition to the promising amyloid-β-directed strategies there are also other possibilities for 
therapeutic intervention. Tau-related agents are a reasonable strategy for the treatment of AD 
since the accumulation of tau protein in neurons is postulated to have severe consequences on 
cellular function (Hardy & Selkoe, 2002). Anti-tau immunotherapy (Godyn et al., 2016) and 
inhibitors of tau aggregation such as Methylene Blue (Schirmer et al. 2011; Stack et al., 2014) 
promote protein degradation and avert tau-associated cytotoxicity. Another reasonable 
therapeutic approach to reduce the risk of dementia includes anti-inflammatory drugs 
(Miguel-Alvarez et al., 2015). The critical role of microglia in the pathogenesis of AD was 
highlighted by GWAS, which discovered that genetic alterations modulating AD risk are 
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enriched in genomic regions that regulate the gene expression of microglial proteins (Huang 
et al., 2017). However, the best way to modulate the immune system without inducing toxic 
effects remains unclear. Although the effectiveness of non-pharmacological lifestyle changes 
including physical exercise, cognitive activity, energy restriction, and social engagement 
(Jedrziewski et al., 2014) in preventing the development of AD after diagnosis seems to be 
highly unlikely, the onset and the progression of the disease could possibly be delayed 
(Barnes & Yaffe, 2011). As AD is a multifactorial disease, a combination of disease-
modifying therapeutics and lifestyle and environmental factors might be in favor of 
prevention. 
 
2.2.2 Necessity of early biomarkers to detect and monitor pathological changes 
A definite diagnosis for AD requires the analysis of post-mortem brain tissue revealing 
neuritic plaques and neurofibrillary tangles. However, physicians rely on different measures 
to diagnose AD clinically on individuals with cognitive impairments. Therefore, the patient’s 
recent history of mental and behavioral deficits is evaluated according to the criteria of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-V criteria) and of the National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association (NINCDS/ADRDA criteria). Physical and 
neuropsychological tests are combined with neuroimaging and biochemical biomarkers to 
specifically diagnose AD dementia. Biomarkers are objectively measurable, indicate or 
mirror either normal or pathological processes in the brain, and help to detect and diagnose 
diseases (Biomarkers Definitions Working Group, 2001). Furthermore they can be used to 
estimate the response to therapy and in the future potentially to individualize treatment 
(Zetterberg, 2017).  
Brain atrophy as a measure of structural tissue loss and general neurodegeneration is assessed 
by magnetic resonance imaging (MRI) (Bobinski et al., 2000; Zarow et al., 2005). Prior to the 
development of pathology-specific Aβ tracers for positron emission tomography (PET), 18F-
fluorodeoxyglucose (FDG) PET was the most widely used imaging biomarker in AD based 
on altered cerebral glucose metabolism in AD patients (Chase et al., 1984; Foster et al., 1984; 
Minoshima et al., 1995; Mosconi et al., 2008). Nowadays, PET amyloid imaging is usually 
used to visualize brain Aβ deposition specifically (Klunk et al., 2004; Villemagne et al., 
2011; Xu et al., 2016). Tracer molecules such as Pittsburgh compound B (PiB) or florbetapir 
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F 18 are injected intravenously, travel trough the blood to the brain, and attach to amyloid 
plaques (Klunk et al., 2004; Clark et al., 2011). Their radiant signal creates an informative 
picture about density and location of fibrillar Aβ deposits (Ikonomovic et al., 2008; Fleisher 
et al., 2011; Sojkova et al., 2011). Although amyloid can accumulate in age in cognitively 
healthy individuals (Driscoll et al., 2011), the presence of a positive amyloid scan in a 
symptomatic patient is a strong indicator of AD (Johnson et al., 2012).  
In addition or alternatively to the very costly PET scans AD can be diagnosed by biochemical 
tests investigating specific fluid biomarkers such as Aβ and tau in the CSF. Aβ42 peptides as 
major components of amyloid deposits (Masters et al., 1985) decline in the CSF of AD 
patients (Motter et al., 1995; Olsson et al., 2016). In line with the imaging biomarkers, CSF 
Aβ42 is sequestered in growing brain aggregates, which is why CSF Aβ42 levels inversely 
correlate with the plaque burden at autopsy (Strozyk et al., 2003; Tapiola et al., 2009). 
However, a better predictor of cognitive performance than amyloid alone is tau 
(Giannakopoulos et al., 2003). Abnormally phosphorylated tau proteins accumulate to 
neurofibrillary tangles within neuronal cells releasing tau as a consequence (Grundke-Iqbal et 
al., 1986). Increased concentrations of either total (t-tau) or phosphorylated tau (p-tau) 
species can be measured in the CSF of AD patients by sensitive enzyme-linked 
immunosorbent assays (ELISA) (Vandermeeren et al., 1993; Vigo-Pelfrey et al., 1995; 
Olsson et al., 2016). Indeed p-tau provides the highest specificity for AD (Zetterberg, 2017). 
However, those biochemical markers should only be used in combination in order to reliably 
diagnose AD (Zetterberg et al., 2003). 
Although APP tg mice lack NFTs, the above-mentioned AD characteristic CSF biomarker 
changes can be replicated remarkably well (Maia et al., 2013). The development of a novel 
and highly sensitive sandwich immunoassay using the single molecule array (SIMOA) 
technology enabled our laboratory to reliably measure murine CSF tau even in pre-depositing 
or non-tg mice. In APPPS1 mice a correlation between brain Aβ reflecting cerebral β-
amyloidosis and an increase in CSF tau could be shown. To further validate the causal 
relationship between CSF tau and β-amyloid pathology, APPPS1 mice were treated with a 
potent BACE inhibitor (NB-360) (Neumann et al., 2015) to suppress Aβ production and the 
influence on tau in the CSF was tested. As mentioned in chapter 2.2.1, NB-360 application 
significantly reduces brain Aβ levels and plaque burden in APP tg mice after one month 
(Neumann et al., 2015). However, in this study NB-360 was administered to early-depositing 
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APPPS1 mice and APP23 mice with moderate pathology for six months. In both mouse 
models brain Aβ as well as amyloid burden were significantly reduced after BACE inhibition 
compared to control littermates revealing levels similar to six months younger animals 
(Schelle et al., 2017). Hence, we published in Alzheimer’s & Dementia: The Journal of the 
Alzheimer’s Association that NB-360 is very effective in lowering brain Aβ levels and 
therefore prevents the progression of cerebral β-amyloidosis without clearing pre-existing Aβ 
plaques (Schelle et al., 2017). Strikingly, not only Aβ was affected by our NB-360 treatment 
but also the age-dependent increase of CSF tau levels was completely prevented (Schelle et 
al., 2017). After short-term BACE inhibition in young APPPS1 and APP23 mice decreased 
CSF Aβ but unaltered CSF tau levels were observed and therefore any direct effects of 
soluble Aβ or the BACE inhibitor itself on CSF tau were excluded (Schelle et al., 2017). In 
conclusion, we have reported a mechanistic link between Aβ deposition and CSF tau 
suggesting CSF tau changes as potential marker to predict the efficiency of BACE inhibitors 
in clinical trials. Furthermore those findings indicate that the effects of BACE inhibition are 
not limited to Aβ, but include downstream pathogenic events highlighting the great potential 
of BACE as target for therapeutic AD intervention. 
Although the treatment prevented further damage with regard to plaque burden and CSF tau 
levels, already present cerebral β-amyloidosis could not be reduced. Furthermore, the drug 
was administered continuously for the entire treatment period. For economical and practical 
reasons the prevention of the disease using only a short therapeutic paradigm applied at the 
critical time point of initial Aβ aggregation would be the goal to solve this health burden.  
A longitudinal study in families with AD mutation-carriers and non-carriers shed light on the 
temporal sequence of pre-symptomatic pathophysiological changes in relation to the expected 
onset of AD symptoms based on the parental age of symptom-onset. It could be shown that 
Aβ42 concentrations in the CSF already started to decline 25 years before the expected onset 
of the clinical disease (Bateman et al., 2012). Aβ deposits were detectable approximately 15 
years before first symptoms arose (Bateman et al., 2012). A few years later, CSF tau 
increased to abnormally high levels, validating again that Aβ aggregation is an early event 
preceding tangle formation (Hardy & Selkoe, 2002; Bateman et al., 2012; Jack & Holtzman, 
2013). Hence, even at the stage of early clinical disease, Aβ deposition already reached a 
plateau and other pathogenic processes such as tau pathology spread and microglia activation 
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have progressed to an advanced state (Bateman et al., 2012; Walker et al., 2013). Although 
only familial AD patients were included in this study, the time course of pathogenic events is 
suggested to be similar for the sporadic form of AD as well (Villemagne et al., 2013). The 
results of this study suggest that pathological changes precede the clinical manifestation of 
AD by up to two decades. Therefore, diagnostic tests as well as clinical trials should be 
moved toward earlier stages of AD or even toward studies in asymptomatic patients (Sperling 
et al., 2014a; Hsu & Marshall, 2017). In other words, Aβ has to be targeted earlier in the 
course of the disease before regular brain function is affected and irreversible 
neurodegeneration has occurred. However, to this end initial Aβ aggregation needs to be 
understood and characterized first in order to develop effective disease-modifying treatments. 
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2.3 Longevity of Aβ seeds and their therapeutic potential 
 
In reference to: 
Persistence of Aβ seeds in APP null mouse brain 
Lan Ye*, Sarah K. Fritschi*, Juliane Schelle, Ulrike Obermüller, Karoline Degenhardt, 
Stephan A. Kaeser, Yvonne S. Eisele, Lary C. Walker, Frank Baumann, Matthias 
Staufenbiel, Mathias Jucker (2015). Nature Neuroscience, 18(11), pp.1559-1561. *contributed 
equally  
 
2.3.1 Prion-like properties of aggregated Aβ 
Despite different clinical manifestations, a diverse group of neurodegenerative diseases 
including AD, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and many 
others share one common pathogenic principle based on the seeded aggregation of specific 
proteins in characteristic patterns and locations (Prusiner, 2012; Jucker & Walker, 2013; 
Walker & Jucker, 2015). Templated protein misfolding and propagation has been 
hypothesized to initiate the pathological transition from a soluble to an aggregated state and 
is called the prion paradigm because it was first investigated in prion diseases. Prions 
(proteinaceous infectious particles) are infectious agents that consist of abnormally folded 
prion protein (PrP) (Prusiner, 1982). Prion diseases are transmissible spongiform 
encephalopathies including Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-
Scheinker disease (GSS), kuru, and fatal familial insomnia (FFI) in humans, scrapie in sheep, 
chronic wasting disease (CWD) of deer and elk, and bovine spongiform encephalopathy 
(BSE) in cows (Prusiner, 1998; Collins et al., 2004). In genetic as well as idiopathic forms 
the constantly generated prion protein (Chesebro et al., 1985; Oesch et al., 1985) misfolds 
and aggregates into PrP seeds (Jarrett & Lansbury, 1993; Prusiner, 1998; Prusiner, 2013). 
This induces a chain reaction forcing naïve PrP proteins into malformation proliferating to 
protofibrils and amyloid assemblies (Jarrett & Lansbury, 1993; Prusiner, 1998; Prusiner, 
2013).  
Recent findings suggest that this prion paradigm based on seeded corruption of naïve proteins 
underlies also other proteopathies including AD (Jucker & Walker, 2013). Although the 
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physiological function of the Aβ peptide is largely unknown, it is constantly produced in the 
brain (Haass et al., 1992) and holds the ability to adopt more aggregation-prone 
conformations. Amyloidogenic proteins such as Aβ seem to follow a nucleation-dependent 
polymerization process (Harper & Lansbury, 1997; Jarrett & Lansbury, 1993; Eisele, 2013). 
The single steps of this kinetic process are described in Figure 2. In vitro studies revealed that 
first of all the natively unfolded Aβ protein misfolds into a kinetically unfavorable 
conformation rich in β-sheet structure and after a series of intermediate states it might 
aggregate into a multimeric nucleus (seed) (Harper & Lansbury, 1997; Jarrett & Lansbury, 
1993). This slow process of initial seed formation is called nucleation phase (lag phase). 
Through conformational conversion, other Aβ molecules are incorporated into the existing 
aggregate. Fragmentation of the progressively growing amyloid fibril generates more Aβ 
seeds leading to a self-propagating process as part of the so called rapid growth phase (Jarrett 
& Lansbury, 1993; Roychaudhuri et al., 2009; Knowles et al., 2011). The initial lag-phase 
preceding amyloid formation can be shortened by the addition of preformed Aβ seeds 
(Harper & Lansbury, 1997; Meyer-Luehmann et al., 2006).  
Inoculation experiments support the nucleation-dependent polymerization of Aβ proteins by 
showing that Aβ deposition can also be induced in vivo following a prion-like mechanism. 
Young, pre-depositing APP tg mice were intracerebrally injected with minute amounts of 
brain homogenates from AD patients and controls (Kane et al., 2000; Walker et al., 2002; 
Meyer-Luehmann et al., 2006). After certain incubation time (lag phase) the animals 
developed cerebral β-amyloidosis in a time- and concentration-dependent manner (Meyer-
Luehmann et al., 2006; Fritschi et al., 2014b). In contrast, extracts from control donors did 
not induce amyloid pathology (Kane et al., 2000; Meyer-Luehmann et al., 2006). To exclude 
the possibilities of induced Aβ lesions due to human-specific factors, brain material from 
aged APP tg donor mice as well as control mice were injected into the hippocampus of tg 
host mice (Meyer-Luehmann et al., 2006; Watts et al., 2011). Again, Aβ was observed to 
aggregate, self-propagate, and spread to neighboring and neuroanatomically connected brain 
regions similar to extracts from AD patients (Walker et al., 2002; Meyer-Luehmann et al., 
2006; Eisele et al., 2009; Hamaguchi et al., 2012; Ye et al., 2015b) and prions (Fraser, 1982; 
Buyukmihci et al., 1983; Kimberlin & Walker, 1986; Rangel et al., 2014). Even Aβ seeds 
applied to the periphery of APP tg mice initiated plaque formation in the brain after a certain 
incubation time, ruling out brain injury or an immunological response at the injection site as 
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reasons for the induced cerebral β-amyloidosis (Eisele et al., 2010; Eisele et al., 2014). 
However, prion disease can be induced de novo in animals that usually would not develop the 
pathology (Prusiner, 1998; Soto, 2011). Therefore, APP tg rodents without Aβ deposits 
within the normal lifespan were inoculated with Aβ seeds and plaque deposition was 
induced. Hence, there was no acceleration of an ongoing process but soluble Aβ peptides 
were triggered to aggregate (Morales et al., 2012; Rosen et al., 2012). Like recombinant prion 
proteins (Legname et al., 2004), synthetic Aβ peptides have only poor potency to aggregate 
(Stöhr et al., 2012). Nevertheless, synthetic Aβ can induce Aβ deposition and amyloid 
plaques in a living cellular environment (Friedrich et al., 2010; Novotny et al., 2016). 
Another feature of prion proteins is the adoption of conformationally distinct amyloid strains 
(Prusiner, 1998; Collinge & Clarke, 2007), a property that could also be confirmed for Aβ 
seeds (Meyer-Luehmann et al., 2006; Heilbronner et al., 2013; Stöhr et al., 2014; Watts et al., 
2014).  
Despite all the similarities between prions and Aβ seeds, until now it seems unlikely that AD 
is infectious in terms of transmissibility from person to person under ordinary circumstances 
(Walker et al., 2016). However, the first evidence for prion-like seeding of Aβ in humans 
came from Jaunmuktane et al. in 2015. In this study, brains of eight people were investigated 
regarding Aβ pathology who were treated with growth hormones isolated from cadaveric 
human pituitary glands and died of CJD between 36 and 51 years of age (Jaunmuktane et al., 
2015). Despite the young age and no present FAD mutation, half of the investigated hormone 
recipients showed significant amounts of cerebral β-amyloidosis (Jaunmuktane et al., 2015). 
This suggests a contamination of the 30 years before isolated and injected material not only 
with PrP prions but also with Aβ seeds (Jaunmuktane et al., 2015; Jucker & Walker, 2015). 
Even in people previously treated with cadaveric growth hormones who died of causes other 
than CJD Aβ pathology was found revealing its independence of the development of clinical 
CJD (Ritchie et al., 2017). However, the investigated subjects lacked cerebral tau pathology 
as well as clinical AD symptoms (Jaunmuktane et al., 2015; Ritchie et al., 2017). Whether 
those lesions would eventually have manifested later in life is unknown. But until the results 
of follow up studies of the surviving growth hormone recipients or other evidences emerge, 
AD is not proven to spread among humans in a sense that the disease-causing agent can be 
acquired from patients or environment and infect another person, like it is the case for prion 
diseases (Beekes et al., 2014; Jucker & Walker, 2015; Walker et al., 2016).  
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Figure 2: Pathological cascade of amyloid β (Aβ) accumulation. Misfolding of the Aβ peptide initiates the 
recruitment and malformation of natively folded Aβ monomers to form an oligomeric nucleus (Aβ seed). After 
this slow nucleation phase the Aβ seed self-propagates and forms amyloid protofibrils due to templated 
misfolding, which later accumulate into amyloid plaques. Within this rapid growth phase those fibrils can be 
fragmented again into smaller Aβ seeds. Addition of preformed seeds shortens the nucleation phase. Targeting 
initial Aβ seeds with anti-amyloid therapies might delay or even prevent cerebral β-amyloidosis (modified from 
Harper & Lansbury, 1997). 
 
2.3.2 Stability and durability of Aβ seeds 
Infectious PrP prions are known to vary in size and stability and to resist even harsh thermal 
and biochemical treatments (Appel et al., 2001; Tzaban et al., 2002; Silveira et al., 2005; 
Wiggins, 2009; Prusiner, 2013). As Aβ seeds seem to be the driving force of AD, the 
robustness and potency of different Aβ species to induce cerebral Aβ deposition is of 
tremendous interest. Comparable to prions, Aβ seeds tend to be very durable agents. This was 
postulated because boiling of Aβ seeds for five minutes still retained seeding capacity 
(Meyer-Luehmann et al., 2006). Even stainless-steel wires coated with dried Aβ-rich brain 
material implanted into brains of APP tg mice were able to induce plaque deposition (Eisele 
et al., 2009). Like prions (Pattison, 1965), Aβ seeds are resistant to inactivation by 
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formaldehyde, discovered by induced Aβ pathology in APP tg hosts inoculated with 
formaldehyde-fixed brain homogenates from AD patients or APP tg mice (Fritschi et al., 
2014a). However, immunodepletion of Aβ-laden extracts as well as formic acid treatment 
resolving the tertiary protein structure prevented cerebral β-amyloidosis in inoculated APP tg 
mice (Meyer-Luehmann et al., 2006). Taken together those results suggest that Aβ seeds are 
extremely robust and Aβ-containing tissue or material should be handled with highest 
caution.  
To assess the seeding capacity of Aβ seeds, brain extracts of APP tg mice were subjected to 
100.000 x g ultracentrifugation and both supernatant and pellet fraction were injected in the 
hippocampus of pre-depositing APP tg mice. Although the supernatant fraction contained 
only less than 1% of total brain Aβ, the soluble fraction induced about 30% of the Aβ plaque 
load compared to the pellet fraction (Langer et al., 2011). Hence, small soluble Aβ seeds 
appear to be the most potent Aβ species. Further characterization involved digestion of Aβ 
seeds by proteinase K (PK). The degree of destruction of soluble Aβ seeds by PK extended 
the sensitivity of larger insoluble seeds to PK neutralization (Langer et al., 2011). Moreover, 
the potency of soluble Aβ species was investigated using a dilution series of soluble brain 
extracts rich in Aβ seeds. In fact, even a 10.000-fold diluted soluble AD brain material 
sample stimulated Aβ pathology in young APP tg hosts (Fritschi et al., 2014b). However, 
CSF from AD patients or aged APP tg mice containing soluble Aβ seeds was not proven to 
be seeding active (Fritschi et al., 2014b).  
The persistence of those very active and potent cerebral Aβ seeds was further investigated in 
our recent study and published in Nature Neuroscience using different APP tg hosts (Ye et 
al., 2015a). APP23, wt, and App null (Calhoun et al., 1999) mice were injected into the 
hippocampus with brain extracts from aged APP tg mice. One, seven, and 30 days post 
inoculation (dpi) the hippocampi of those mice were assessed biochemically. One day post 
inoculation the injected human Aβ was present in all three murine hosts at similar levels, 
whereas at seven and 30 dpi human Aβ decreased below detection in App null and wt mice 
(Ye et al., 2015a). Although another study revealed that murine Aβ co-deposits in human 
APP overexpressing mice (Mahler et al., 2015), in this experiment the low levels of mouse 
Aβ in wt mice did not prevent the clearance of applied Aβ seeds. However, in APP23 mice 
propagation of the injected Aβ seeds could be detected (Ye et al., 2015a). Hence, cerebral β-
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amyloidosis not only depends on the concentration of seeds applied but also on the 
availability of sufficient soluble Aβ from the host to be incorporated into the exogenously 
applied seeds. Reinoculations (second passage) of the hippocampi extracted from Aβ seed-
injected App null mice into APP23 hosts were carried out and revealed residual seeding 
capacity. Already after four but even more prominent after eight months incubation time the 
App null 30 dpi hippocampal extract with no detectable Aβ induced amyloid deposition in an 
APP tg host (Ye et al., 2015a). Due to the unexpected results the experiment was repeated 
and the primary incubation time in the App null mice was extended up to six months. Again, 
the analyzed hippocampi revealed Aβ levels below detection. However, second passage 
inoculation of this hippocampal extract revealed robust induction of cerebral β-amyloidosis 
in APP tg mice (Ye et al., 2015a). In contrast, no induction was observed using wt extracts 
(Ye et al., 2015a). Consequently Aβ seeds in App null mice, despite the absence of 
replication and the presence of active clearance mechanisms, regained their pathogenicity and 
seeding activity as soon as host-derived Aβ became available again. The discovery of the 
extraordinary stability of Aβ seeds in the brain up to 180 days supports the idea that AD 
pathogenesis is initiated before Aβ deposition becomes detectable and explains the long 
silent lag phase seen in AD patients prior to symptom-onset (Bateman et al., 2012; De 
Strooper & Karran, 2016). Therefore, therapies for AD need to target those durable Aβ seeds 
at an early stage because apparently they are able to hide in yet unknown cellular 
compartments without loosing their toxicity. Ideally, the initial seed formation should be 
prevented at the first place. 
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2.4 Targeting initial Aβ seeds for the prevention of Alzheimer’s disease 
 
In reference to: 
Prevention of cerebral β-amyloidosis by targeting initial Aβ seeds 
Juliane Schelle, Sarah K. Fritschi, Ulrike Obermüller, Lisa M. Häsler, Marius Lambert, 
Stephan A. Kaeser, Ulf Neumann, Derya R. Shimshek, Matthias Staufenbiel, Mathias Jucker 
(2017). Manuscript in preparation.  
 
2.4.1 Clinical trials for Alzheimer’s disease and possible reasons for recent failures 
The fact that one out of nine people older than 65 years and one out of three for those over 
age 85 suffer from AD (Alzheimer’s Association, 2014), has justified many scientific 
research approaches as well as clinical studies throughout the last decades. As mentioned in 
chapter 2.2.1, approved drugs for AD only relieve symptoms and do not change the course of 
the disease. Although we have learned a lot about AD pathophysiology and evidence for the 
lowering and neutralization of Aβ as a useful therapeutic approach has accumulated, many 
phase II and III clinical trials investigating disease-modifying agents have failed as displayed 
in Table 1 (Graham et al., 2017). This chapter is dedicated to potential causes for those 
clinical trial failures.  
For example, the non-selective γ-secretase inhibitor Semagacestat (Eli Lilly & Co.) 
effectively lowered brain Aβ levels but induced serious side effects and worsened cognitive 
performance in a phase III trial due to missing substrate selectivity (Doody et al., 2013; De 
Strooper, 2014). Therefore, instead of stopping proteolysis, γ-secretase modulators are in 
favor now that shift the ratio of different Aβ species toward less toxic ones. Not only γ-
secretase blockers, but also many BACE inhibitors such as RG7129 (Roche), LY2811376 (Eli 
Lilly & Co.), and LY2886721 (Eli Lilly & Co.) failed to manage off-target effects and to pass 
toxicology studies.  
Despite the disappointment about all failed clinical trials, numerous lessons can be learnt. 
Further critical examination of the failed antibodies as well as BACE inhibitor studies 
revealed that some of the enrolled subjects might not have had AD as indicated by negative 
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amyloid PET scans (Karran & Hardy, 2014; Salloway & Sperling, 2015). Fluid as well as 
imaging biomarkers including CSF Aβ, CSF t-tau and p-tau, PET amyloid, and structural 
imaging with MRI should be included to select only amyloid-positive trial subjects that 
presumably develop AD (Morris et al., 2009; Lim et al., 2013; Vos et al., 2013). This will 
improve the design of clinical studies and will increase the possibility to detect treatment 
effects in the future.  
Furthermore appropriate clinical endpoints need to be selected. Recently, the FDA issued 
new guidelines for clinical trials in early AD. Although AD studies in demented people 
require both cognitive and functional outcome measures, only a single cognitive endpoint 
needs to be achieved for trials in preclinical AD (Kozauer & Katz, 2013). 
In addition to the above-mentioned issues there are many other possible explanations for 
unsuccessful individual agents such as a lack of drug potency, insufficient compound safety, 
and the presence of co-pathologies. However, most likely disease severity, target 
engagement, and the advanced AD stage of selected subjects caused most of the recent 
failures in clinical AD trials. For example, Verubecestat (Merck & Co, Inc.), a small 
molecule non-selective BACE inhibitor, showed good tolerability without withdrawals due to 
side effects and CSF Aβ reductions of up to 90% in mild to moderate AD patients in a phase 
II/III EPOCH trial (Kennedy et al., 2016) but failed to significantly slow disease progression. 
Also the monocloncal antibody Bapineuzumab (Pfizer, Inc., Johnson & Johnson 
Pharmaceutical Company, Janssen Pharmaceutica, Elan Pharmaceuticals, Inc.) with its N-
terminal Aβ epitope binding Aβ monomers, oligomers, and plaques significantly decreased 
PET amyloid signals as well as CSF p-tau levels (Rinne et al., 2010; Blennow et al., 2012) 
but induced severe side effects such as ARIA with edema and missed clinical endpoints in 
mild to moderate AD patients (Sperling et al., 2011). Thus, Bapineuzumab should not be used 
to treat patients with mild to moderate AD (Abushouk et al., 2017) similar to Verubecestat, 
which is currently tested in prodromal AD patients. Another example and the most recent 
disappointment in clinical AD trials is Solanezumab (Eli Lilly & Co.), described in chapter 
2.2.1. No ARIA was evoked but also no cognitive benefit could be measured in moderate AD 
patients, leading to the discontinuation of this arm of the trial (Doody et al., 2014). In patients 
with only mild AD the same treatment showed slight improvements in cognitive tests over an 
18-month period (Doody et al., 2014; Siemers et al., 2016) but failed to significantly decrease 
the rate of cognitive decline and CSF Aβ profile. As described in chapter 2.2.2, profound 
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brain alterations occur long before dementia can be diagnosed. These findings may explain 
why therapeutic intervention at a moderate AD stage failed in all previous clinical trials. The 
treatment initiated in symptomatic patients was probably too late to ameliorate symptoms 
because Aβ deposition and neuronal loss had already begun and progressed for many years 
(Graham et al., 2017). At this point, treatments may have become ineffective and additionally 
cause a lot of side effects. Eventually the efficacy and safety of therapeutics can be increased 
if tried on pre-symptomatic subjects positive for AD imaging and CSF biomarkers and 
therefore at high risk to develop AD. Such secondary prevention trials aim to treat the 
underlying pathophysiology in order to prevent cognitive symptoms from ever developing or 
at least delay the onset of the disease (Graham et al., 2017; Hardy & De Strooper, 2017).  
Five large secondary prevention trials, depicted in Table 2, have started recruiting cognitively 
normal subjects and include: 1) the Alzheimer’s Prevention Initiative (API) Autosomal-
Dominant AD (ADAD) trial, 2) the API APOE4 trial, 3) the Dominantly Inherited Alzheimer 
Network (DIAN) Trials Unit (DIAN-TU), 4) the Anti-Amyloid Treatment in Asymptomatic 
Alzheimer’s Disease (A4) trial, and 5) the TOMORROW trial (Hsu & Marshall, 2017).  
The API-ADAD and API-APOE4 trials have been enrolling cognitively healthy subjects who 
carry a PSEN1 mutation or are homozygous for the APOE4 risk allele, respectively (Hsu & 
Marshall, 2017). The API-ADAD trial (Mullard, 2012) is using the Aβ specific antibody 
Crenezumab (Genentech, Inc.) described in chapter 2.2.1. The completion of the trial is 
estimated in 2020. The API-APOE4 trial is testing CAD106 as an active amyloid vaccine 
(Winblad et al., 2012) as well as the BACE inhibitor CNP520 (Novartis International AG, 
2015) both developed by Novartis Pharmaceuticals.  
The DIAN trials focus on families suffering from FAD carrying PSEN1, PSEN2, or App 
mutations (Mullard, 2012; Moulder et al., 2013; Hsu & Marshall, 2017). Cognitively normal 
individuals 15 years before the expected symptom onset, MCI, or mild AD subjects within 
those families are treated with Solanezumab (Eli Lilly & Co.) and/or Gantenerumab (Chugai 
Pharmaceutical Co., Ltd., Hoffmann-La Roche) (Ostrowitzki et al., 2012), the BACE 
inhibitor JNJ-54861911 (Janssen Pharmaceutica, Shionogi), or placebo. Two-year follow up 
studies have been conducted assessing cognitive measures, neuroimaging, and CSF 
biomarkers.  
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The first prevention trials in pre-symptomatic subjects at high risk to develop LOAD based 
on abnormal amyloid PET scans are conducted in Australia and are called A4 and A5 study 
(Sperling et al., 2014b; Hsu & Marshall, 2017). With regards to the A4 trial, a total of 5000 
individuals should receive monthly infusions of either Solanezumab (Eli Lilly & Co.) or 
placebo for slightly more than three years. The A5 trial is evaluating the efficiency of 
Janssen’s BACE inhibitor in about 2000 people. Similar to the DIAN trials, cognitive tests 
will be the primary outcome measure followed by neuroimaging and biochemical 
biomarkers.  
The TOMORROW trial is the only study that is not based on the amyloid hypothesis but 
rather focuses on the genetic enrichment of the translocase of outer mitochondrial membrane 
40 homolog (TOMM40) gene, which is linked to APOE ε4 gene (Hsu & Marshall, 2017). 
Both genes predict cognitive aging in late onset AD (Roses et al., 2010; Caselli et al., 2012). 
They plan to enroll 6000 cognitively normal individuals and treat them randomly with the 
mitochondrial targeting agent Pioglitazone (Takeda Pharmaceutical Company), which is an 
approved anti-diabetic drug (Geldmacher et al., 2011; Sato et al., 2011). 
Table 2: Current secondary prevention trials in Alzheimer’s disease  
Trial Intervention Study sample Location Start Duration 
API-ADAD Crenezumab Presenilin-1 carriers Colombia 2013 5 years 
API-APOE4 CAD106, CNP520 APOE4 homozygotes 
North 
America, 
Europe 
2015 5 years 
DIAN-TU Gantenerumab, Solanezumab 
Cognitively normal, MCI, 
or mild AD mutation 
carriers 
U.S., Canada 2013 2 years 
A4 Solanezumab 
Cognitively normal people 
with abnormal amyloid 
PET 
U.S., 
Canada, 
Australia 
2014 3.25 years 
TOMORROW Pioglitazone 
Cognitively normal people 
with genetic risk of 
TOMM40 and APOE4 
Worldwide 2014 5 years 
 
Updated summer 2017; A4 = Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease; AD = 
Alzheimer’s disease; ADAD = Autosomal-Dominant AD; API = Alzheimer’s Prevention Initiative; APOE4 = 
apolipoprotein E ε4; DIAN-TU = Dominantly Inherited Alzheimer Network Trials Unit; MCI = mild cognitive 
impairment; PET = positron emission tomography; TOMM40 = translocase of outer mitochondrial membrane 
40 homolog (adapted from Hsu & Marshall, 2017) 
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2.4.2 Delay of cerebral β-amyloidosis by short and early combination therapy 
The failed clinical trials using anti-amyloid drugs in mild to moderate AD patients suggest 
that treatment during or even at the beginning of the long prodromal phase is the most 
promising therapeutic approach (De Strooper & Karran, 2016). Since preclinical treatment 
clearly causes ethical and practical difficulties, tg animals should be used first in order to 
predict the outcome of certain treatment strategies. Indeed, animal data mirrored accurately 
the negative outcomes, namely the unsuccessful clearance of established plaques, in clinical 
trials testing Solanuzumab (Eli Lilly & Co.) (DeMattos et al., 2001). Also BACE inhibitors 
used experimentally in mice prevented the progression of plaque development but did not 
clear existing Aβ deposits (Fukumoto et al., 2010; Schelle et al., 2017) similar to the findings 
obtained in human subjects. In mice it appears to be fairly easy to determine the onset of 
plaque deposition and CSF biomarker changes (Sturchler-Pierrat et al., 1997; Radde et al., 
2006; Maia et al., 2013; Maia et al., 2015). Because mixing Aβ seeds with Aβ specific 
antibodies reduced the induction of cerebral β-amyloidosis in inoculated APP tg hosts 
(Meyer-Luehmann et al., 2006) and Aβ seeds could be at least partially degraded in App null 
mice (Ye et al., 2015a), both anti-Aβ immunization and a reduction in Aβ generation by 
secretase inhibition appear to be rational therapeutic paradigms to reduce Aβ seeds. 
Many studies that are explained in chapter 2.1.2 suggested that Aβ aggregation is the trigger 
of a sequence of pathogenic events, which once initiated become independent of Aβ and at a 
final stage cause AD dementia (Karran et al., 2011). In line with this, a recent aging study 
indicates that early Aβ seeds are the most active ones in terms of seeding capacity and 
display the greatest seeding potency when inoculated in young, pre-depositing APP tg mice 
(Ye et al., 2017). Hence, a combination therapy should be applied during this critical time 
window as indicated in Figure 2, when the first Aβ seeds emerge, clearing Aβ seeds with an 
Aβ specific antibody and blocking the production of soluble Aβ by BACE inhibition. 
Although BACE inhibitors are less expensive and have clearer endpoint measures than 
antibodies, a combination of both anti-Aβ approaches given at an early time point might 
provide better clinical outcomes. To prove that Aβ seeds can be inactivated by short and 
early Aβ immunotherapy, the plaque-clearing Aβ specific antibody Beta-1 (β1) was injected 
(Pfeiffer et al., 2002; Meyer-Luehmann et al., 2006) into young, Aβ seed-inoculated APP23 
mice once daily for five consecutive days. This short immunization was sufficient to 
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ameliorate the induction and propagation of Aβ aggregation four months later. Afterwards, 
the β1 was combined with the potent BACE inhibitor NB-360, which was previously shown 
to effectively reduce Aβ in CSF and brain as well as to stop amyloid formation (Schelle et al., 
2017). The combination of NB-360 and β1 was applied to young APP tg mice at a defined 
pre-depositing stage targeting first endogenous Aβ seeds. This short and early intervention of 
initial Aβ aggregation decreased Aβ seeds acutely but also delayed the onset of Aβ plaque 
pathology even after discontinuation of the treatment for several months. The findings could 
be replicated in APP51 mice overexpressing human wt APP, which suggests that targeting 
amyloid seeds shortly but at a pre-amyloid stage and thereby interfering with the initial 
seeding phase of amyloid formation by Aβ vaccination and BACE inhibition, might be an 
effective and promising therapeutic approach to prevent cerebral β-amyloidosis and 
eventually early- and late-onset AD. 
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2.5 Concluding remarks and outlook 
Although effective disease-modifying drugs for the delay or even the prevention of AD still 
remain to be verified, many scientific studies and clinical trials have contributed to a basic 
understanding of the disease throughout the last decades. Since the publication of the amyloid 
hypothesis 25 years ago, many papers have revised the linearity of pathologenic events and 
have presented highly complex and interacting pathological pathways of proteostasis, lipid 
metabolism, vasculature, glial activation, and neuronal circuitries. However, the original 
sequence of pathogenic events still appears to hold its ground: 1) Aβ peptides aggregate and 
form Aβ seeds in a self-propagating nucleation dependent process; 2) inflammatory 
responses, tau pathology, synaptic dysfunctions, and neuronal loss follow as downstream 
events; 3) the combination of Aβ and tau pathologies characterizes AD dementia, despite the 
fact that almost everyone develops some tau pathology during aging, whereas only a subset 
of individuals show cerebral β-amyloidosis (Hardy & Higgins, 1992; Hardy & Selkoe, 2002; 
Selkoe & Hardy, 2016). Although the complex biology of the disease offers numerous flanks 
for attack by therapies, the previous chapters summarize the rationale behind Aβ as the most 
promising therapeutic target.   
One of the presented studies showed that the initial trigger of the disease pathology can be 
targeted by effective BACE inhibition. Reducing the β-secretase activity prevented plaque 
formation and additionally affected downstream AD pathophysiology such as increasing CSF 
tau concentrations. Therefore BACE inhibitors not only serve as potent anti-amyloid drugs 
but their effectiveness can also be monitored in clinical trials by evaluation of tau levels in 
the CSF.  
However, BACE inhibitors or other Aβ lowering agents applied to mild to moderate AD 
patients have resulted in negative clinical trial outcomes due to induced side effects and/or 
unaltered cognitive performance. The fact that pathological changes become measurable 
decades before first AD symptoms arise (Bateman et al., 2012), suggests the need for better 
characterization of this long pre-symptomatic period and earlier therapeutic intervention. 
A recent paper from our laboratory confirms that the most seeding-active Aβ aggregates 
occur at early stages of the amyloid formation (Ye et al., 2017). In APP tg mice it could 
already be shown experimentally that targeting Aβ using a γ-secretase inhibitor prior to 
deposition has the most significant impact on cerebral β-amyloidosis compared to less 
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effective treatments at later stages (Das et al., 2012). However, lowering soluble Aβ 
generation to a certain level did not prevent amyloidosis completely and might not be 
sufficient to tackle Aβ seeds (Das et al., 2012; Schelle et al., 2017). The described 
characterization of Aβ seeds unveiled their tremendous durability as well as their ability to 
regain pathogenic activity after a silent phase of up to six months. Those experiments confirm 
the high therapeutic potential of targeting early Aβ seeds for AD treatment.  
On that account, a combination of two anti-Aβ strategies seems to be a reasonable therapeutic 
approach. That is why the age of potential Aβ seed formation was determined in APP tg 
mice, which were then treated with a combination of a BACE inhibitor to turn off Aβ 
production and a non-selective Aβ antibody to reduce Aβ seeds during this critical time 
window. After discontinuation of the treatment brain Aβ levels as well as plaque burden were 
still significantly reduced compared to controls. However, comparing the levels to a 1.5 
months younger control group revealed a shift in pathology by only the treatment period. 
Therefore amyloid pathology was successfully delayed, although only by the length of the 
treatment.  
Hence, a β-secretase inhibitor should be combined with an antibody that selectively binds Aβ 
seeds over monomers. Applied at the beginning of Aβ seed formation this combinational 
therapy should prevent the development of plaques, downstream effects, and therefore AD. 
Furthermore, validated and standardized biomarkers should be included in each trial to help 
identify at-risk participants and synchronize AD measures. Asymptomatic individuals 
endangered to develop AD should be treated at the right time point with a combination of 
disease-modifying drugs such as BACE inhibitors and passive Aβ seed immunization 
strategies. Taken together, this early anti-Aβ seed-specific therapy interfering with the 
pathological cascade should enable us to prevent this devastating disorder, deescalate this 
burdensome health situation, and change people’s lives. 
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Prevention of tau increase in cerebrospinal fluid of APP transgenic mice
suggests downstream effect of BACE1 inhibition
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Abstract Introduction: The inhibition of the b-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is
a main therapeutic approach for the treatment of Alzheimer’s disease (AD). We previously reported
an age-related increase of tau protein in the cerebrospinal fluid (CSF) of amyloid b (Ab) precursor
protein (APP) transgenic mice.
Methods: APP transgenic mice were treated with a potent BACE1 inhibitor. CSF tau and CSF Ab
levels were assessed. A novel high-sensitivity tau sandwich immunoassay was developed.
Results: We demonstrate that long-term BACE1 inhibition prevents CSF tau increase both in early-
depositing APP transgenic mice and APP transgenic mice with moderate Ab pathology.
Discussion: Our results demonstrate that BACE1 inhibition not only reduces Ab generation but also
downstreamAD pathophysiology. The tight correlation between Ab aggregation in brain and CSF tau
levels renders CSF tau a valuable marker to predict the effectiveness of BACE1 inhibitors in current
clinical trials.
! 2016 the Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.
Keywords: Alzheimer’s disease; Biomarker; CSF; Tau; BACE1 inhibitor; Treatment
1. Introduction
The microtubule-associated protein tau (tau) and amy-
loid b (Ab) peptides are the main components of neurofibril-
lary tangles and amyloid plaques, respectively, that in turn
are the pathologic hallmarks of Alzheimer’s disease (AD).
Moreover, tau and Ab levels in the cerebrospinal fluid
(CSF) are well-established biomarkers for AD progression
[1]. While CSF Ab—in particular the species ending with
amino acid 42 (Ab42)—decreases with disease progression,
total and phosphorylated tau increase. We previously
showed that transgenic mouse models overexpressing hu-
man amyloid precursor protein (APP tg) replicate these
AD CSF biomarker changes remarkably well [2]. While
the CSFAb42 decrease was presumably caused by sequestra-
tion of Ab42 to growing amyloid plaques, the observation of
increased (murine) tau in CSF of APP tg mice was more sur-
prising because they lack neurofibrillary tangles and overt
neuron loss [2].
A widely followed therapeutic concept in AD is the
reduction of Ab production through inhibition of b-site
*Corresponding authors. Tel.: 149 7071 29 81947; Fax: 149 7071 29
4521.
E-mail address: mathias.jucker@uni-tuebingen.de (M.J.), stephan.
kaeser@uni-tuebingen.de (S.A.K.)
http://dx.doi.org/10.1016/j.jalz.2016.09.005
1552-5260/! 2016 the Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.
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amyloid precursor protein-cleaving enzyme 1 (BACE1). A
number of BACE1 inhibitors (BACEi) are currently being
tested in clinical trials [3]. Their pharmacodynamic activity
is primarily assessed by the reduction of Ab levels in the
CSF after short-term treatment. Long-term application is
typically monitored by the suppression of amyloid plaque
formation as shown in preclinical studies [4–6].
To test for downstream effects of BACE1 inhibition and
to support the hypothesis of a causal relationship between
CSF tau and b-amyloidosis, we treated APP tg mice with a
potent BACEi (NB-360; Novartis, Basel, Switzerland) [6].
In addition, we developed a novel tau assay with very high
sensitivity. Our results demonstrate that the administration
of NB-360 for 6 months did not only block Ab aggregation
and deposition but also completely abolished the age-
dependent increase of CSF tau in two different APP tg
mouse lines. These findings are consistent with a linkage be-
tween amyloid increase and tau dysfunction and demon-
strate downstream effects of BACE1 inhibition on tau.
Thus, CSF tau levels cannot only be used to monitor AD pro-
gression but might also become an indispensible marker to
predict the efficiency of BACEi in clinical trials.
2. Methods
2.1. APPPS1 mice
Male and femaleAPPPS1micebetween1.5 and19months
of age and age-matched nontransgenic littermates were bred
at the Hertie Institute for Clinical Brain Research (T€ubingen,
Germany). APPPS1 mice have been generated and are main-
tained on a C57BL/6J background and co-express human
K670M/N671L–mutatedAPP and L166P-mutated presenilin
1 under the control of a neuron-specific Thy1 promoter
element [7]. They develop first Ab plaques after 6 weeks of
age and show no gender effect. All micewere kept under spe-
cific pathogen-free conditions. The experimental procedures
were undertaken in accordancewith the veterinary office reg-
ulations of Baden-W€urttemberg (Germany) and approved by
the local animal care and use committees.
2.2. APP23 mice
Male heterozygous APP23 mice (15- to 21.5-month-old)
[8] were all bred at the Hertie Institute for Clinical Brain
Research. APP23 mice express the K670M/N671L–mutated
human APP under control of the neuron-specific Thy1 pro-
moter element at about sevenfold over endogenous (murine)
APP. The mice were initially generated on a B6D2 back-
ground but have since been bred with C57BL/6J mice over
more than 20 generations. APP23 mice have been reported
to develop plaques beginning at 6 to 8 months of age, and
plaque development is faster in females than in males
[8,9]. Therefore, only male animals were used for this
study. All mice were kept under specific pathogen-free con-
ditions. The experimental procedures were conducted
in accordance with the veterinary office regulations of
Baden-W€urttemberg (Germany) and were approved by the
local animal care and use committees.
2.3. BACEi treatment of APP transgenic mice
For the long-term treatment, 1.5-month-old male and fe-
male APPPS1 as well as 15-month-old male APP23 mice
were fed with food pellets containing the BACEi NB-360
[6,10] for 27 and 29 weeks, respectively. The selected dose
(0.5 g inhibitor/kg food pellets) yielded brain exposure
similar to the 100 mmol/kg oral dose previously described
[6]. Average plasma and brain levels of NB-360 over
24 hours for this dose were 1.2 and 4.8 mM, respectively.
Age-matched control mice received control pellets without
the drug for the same time period. For the short-term exper-
iment, male and female APPPS1 mice (2 months of age) and
male APP23 mice (3 months of age) were fed with NB-360
or control pellets for one week. Food pellets were available
ad libitum until the mice were killed. Animals were moni-
tored weekly during the entire treatment time. There were
no differences in food consumption and body weight be-
tween BACEi-treated mice and control mice.
2.4. CSF collection and tissue harvesting
For CSF collection, we adapted and refined protocols that
were published previously [2,11]. Briefly, CSF was collected
within a fixed time period of 4 hours to minimize circadian
CSFAb variations [12]. The mouse was deeply anesthetized
with ketamine (100 mg/mL) and xylazine (10 mg/mL) and
kept on a heating pad during the whole procedure to avoid
hypothermia. Surgery was done under a dissecting micro-
scope. The skin was opened by an incision from the bregma
to the occipital bone and fixed bymeans of a colibri retractor.
Underlying tissue and neck muscles were separated bluntly
and kept apart using a retraction system (Fine Science Tools)
to expose the cisterna magna with the overlaying dura. For
the collection, the mouse was kept in a horizontal position
and the head was bent over (approximately 45!) but not
fixed. The dura was carefully perforated with a 30-gauge
needle, and the CSF was collected with a GELoader Tip (Ep-
pendorf) shortened by about 2 cm at the tip. CSF samples
were immediately centrifuged at 2000g for 10 minutes at
room temperature, assessed macroscopically for blood
contamination, aliquoted (5 mL) into polypropylene tubes
(Eppendorf), snap-frozen in liquid nitrogen, and stored at
280!C until use. After CSF collection, mice were perfused
with ice-cold sterile phosphate-buffered saline (PBS). The
brain was removed and one hemisphere was snap-frozen in
dry ice or liquid nitrogen and stored at 280!C until use.
The other hemibrain was fixed in 4% paraformaldehyde
with 0.1 M PBS, pH 7.6, for 48 hours at 4!C, immersed in
30% sucrose in PBS for an additional 48 hours at 4!C,
snap-frozen in 2-methylbutane, and stored at 280!C.
Mass spectrometry analysis of CSF samples for hemoglo-
binwas done in thepast to refine theCSFcollection technique.
J. Schelle et al. / Alzheimer’s & Dementia 13 (2017) 701-709702
	   59	  
However, in the present study, no influence of rarely detected
small blood pellets on CSF tau levels was found.
2.5. Biochemical analysis of brain tissue
Forebrains (hemibrains without cerebellum) from APP23
and APPPS1 mice were homogenized at 10% (wt/vol) in ho-
mogenization buffer (50 mM Tris pH 8.0, 150 mM NaCl,
5 mM EDTA, and protease/phosphatase inhibitor cocktail
from Thermo Scientific) at 4!C using 7 mL lysing tubes
with 2.8-mm ceramic beads and a tissue homogenizer (Pre-
cellys Bertin, Montigny-le-Bretonneux, France), twice at
5500 rpm for 10 seconds. The homogenized brain tissue
was aliquoted and stored at 280!C until use. For Ab mea-
surements, the homogenates were extracted as follows: ali-
quots were thawed on ice, mixed 1:3.2 with cold formic
acid (FA) (minimum 96% purity; Sigma, St. Louis, MO,
USA), sonicated for 35 seconds at 4!C, and spun at
25,000g at 4!C for 1 hour. The supernatant was collected
as the “FA-soluble fraction” and equilibrated (1:20) in
neutralization buffer (1 M Tris base, 0.5 M Na2HPO4,
0.05% NaN3).
2.6. Ab measurement in CSF and brain extracts
Ab40 (Abx–40) and Ab42 (Abx–42) concentrations in CSF
and brain extracts from APP transgenic mice were deter-
mined with an electrochemiluminescence-linked immuno-
assay using the V-PLEX Ab Peptide Panel 1 (6E10) Kit
(Meso Scale Discovery, Gaithersburg, MD, USA). CSF
was diluted 1:14 in buffer (Diluent 35, Meso Scale Discov-
ery) and analyzed according to the manufacturer’s instruc-
tions. FA-soluble total brain extracts were diluted up to
1:300 in buffer (Diluent 35, Meso Scale Discovery) before
measurement. Data analysis used MSD DISCOVERY
WORKBENCH software 2.0. Internal reference samples
were used as controls in every plate.
2.7. Ultrasensitive sandwich immunoassay for tau
measurements
For measurement of murine tau, a bead-based immuno-
assay was developed using Single Molecule Array (Simoa)
technology (Quanterix, Lexington, MA, USA). A large set
of anti-tau antibodies had initially been checked for reac-
tivity with murine tau, running 10% (wt/vol) brain homog-
enates from tau-deficient (B6.129X1-Mapttm1Hnd)
[13], human tau transgenic (C57BL/6J-Tg[Thy1-
MAPT*P301S]) [14], and wild-type (C57BL/6J) mice on
Western blots (12% Bis-Tris PAGE; Thermo Scientific).
Murine tau reactive antibodies were tested in a customized
bead-based multiplex assay (Luminex, Austin, TX, USA)
to select suitable antibody pairs. All antibodies were tested
as capture and detection antibodies, and the most prom-
ising pairs (based on initial assessment of standard curve
behavior and parallelism experiments) were transferred
and further evaluated on the Simoa platform (Quanterix).
The capture antibodies were immobilized on paramagnetic
microparticles and the detection antibodies were bio-
tinylated following standard procedures. Recombinant mu-
rine tau-430 was used as calibrator protein. ADx202 (ADx
NeuroSciences, Gent, Belgium) for capturing and 77E9
(BioLegend, San Diego, CA, USA) for detection turned
out to be the best performing antibody pair. Both anti-
bodies bind to the proline-rich domain of tau, recognizing
the region 218–225 (ADx202) and 185–195 (77E9) of the
human sequence (or 207–214 and 174–184 of the murine
sequence, respectively).
The assay was thoroughly validated before application in
sample screening. Assessment of sensitivity and assay dy-
namic range revealed a lower limit of detection at 0.34 pg/
mL and lower and upper limit of quantification at 0.69 and
600 pg/mL, respectively (repeated measurement in indepen-
dent assays; criteria: recovery 75%–125%, CV, 25%). CV
of intra-assay precision was 6.9% (n5 20); inter-assay pre-
cision (low-, mid-, and high-concentration sample) showed a
CV between 6.6% and 21.5% (triplicates over four indepen-
dent assay runs). Parallelism analyses of pooled CSF from
C57BL/6J wild-type mice showed 115%, 107%, 101%,
and 77% recovery of endogenous tau when the final dilution
was 20, 40, 80, and 160 times, respectively. (The average of
all recalculated concentrations was considered as the 100%
reference value.) Thus, murine CSF samples were measured
in duplicates at a final dilution of 1:80. Specificity of the
assay was confirmed with samples from tau null mice [13].
Spike-in recovery in native mouse samples was 121% to
132% throughout the assay range.
Samples were processed using a two-step assay protocol
and measured on a HD-1 Analyzer (Quanterix). Aweighted
(1/Y2) four-parametric logistics was used for curve fitting
and calculation of tau protein content in mouse samples.
All CSF tau measurements were done within a time window
of 4 months. During this time, the assay performance was
stable according to the standard curve and quality control
(QC) samples (i.e., within a range of 1/2 2 SDs).
Because of the limited amount of mouse CSF, diluted and
spiked mouse blood plasma was used for internal assay QC.
In each run, three QC samples at low, mid, and high concen-
trations of murine tau were measured in duplicates at a final
dilution of 1:8. To exclude potential matrix effects on paral-
lelism of blood samples, pooled EDTA plasma from C57BL/
6J mice was assessed and revealed 101%, 97%, 100%, and
102% recovery of endogenous tau at the final dilution of 4,
8, 16, and 32 times, respectively.
2.8. Histology and immunohistochemistry
After freezing, fixed brains were cut into serial 25-mm-
thick coronal sections using a freezing-sliding microtome.
The sections were collected in tissue cryoprotection solution
(35% ethylene glycol, 25% glycerol in PBS) and stained im-
munohistochemically according to previously published
protocols using anti-Ab polyclonal antibody CN5, a follow
J. Schelle et al. / Alzheimer’s & Dementia 13 (2017) 701-709 703
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up version of CN3 (1:2000) [2]. According to standard pro-
tocols, sections were counterstained with Congo red for am-
yloid detection.
2.9. Stereological analysis of total Ab plaque load
Ab plaque load was quantified in the neocortex of a repre-
sentative section from an Ab-immunostained set of every
12th systematically sampled, serial, coronal section. A mi-
croscope equipped with a motorized x–y–z stage coupled
to a video microscopy system and the Stereo Investigator
software (MicroBrightField, Inc., Williston, VT, USA) was
used as previously described [15]. The person who per-
formed the analysis was blinded to the treatment groups.
The total Ab load (percentage) was determined by calcu-
lating the areal fraction occupied by CN5-positive staining
in two-dimensional sectors (20! /0.45 objective).
2.10. Statistical analysis
JMP (version 11.2) andGraphPadPrism (version 6.0)were
used for statistical analyses and graphics. Normal distribution
was assessed using the Shapiro-Wilk test. Non–normally
distributed variables were logarithmically transformed. In
all cases, statistical significancewas set at P, .05. All values
are expressed as means6 standard errors of mean.
3. Results
3.1. Age-related increase of tau in CSF of APPPS1 mice
We have previously reported an age-dependent increase
of CSF tau in APP tg mouse models, concomitant with the
progression of cerebral b-amyloidosis [2]. However, the
commercially available assay that we used originally was
not sensitive enough to reliably measure murine CSF tau
in non-tg and young (pre- or early-depositing) APP tg
mice. Thus, we now developed a novel sandwich immuno-
assay using the Simoa technology, which improved sensi-
tivity about 100-fold compared with other immunoassay
platforms (for assay development and validation, see
Supplementary Fig. 1).
CSF was collected for tau quantification from cohorts of
APPPS1 mice and non-tg littermates between 1.5 and
19 months of age. CSF tau in APPPS1 mice revealed an
age-dependent increase of up to sevenfold compared with
the early-depositing phase and non-tg control mice
(Fig. 1A). Our newly developed assay almost completely
discriminated APPPS1 from non-tg control mice already at
Fig. 1. Age-dependent increase of CSF tau and brain Ab in APPPS1 mice. (A) CSF tau was measured in 1.5- to 19-month-old male APPPS1 mice and non-
tg littermates (n 5 7–15 per group) using a highly sensitive novel tau assay (Supplementary Fig. 1). Two-way analysis of variance (ANOVA) revealed sig-
nificant age! genotype interaction [F(4, 100) 5 45.8, P , .001]. Notably, the Tukey post hoc test revealed that CSF tau was already significantly increased
in the 3-month-old APPPS1 mice compared with age-matched non-tg littermates (P , .001) and also compared with the 1.5-month-old APPPS1 mice
(P , .05). Detailed analysis of the CSF tau levels in the non-tg mice (right panel) revealed a transient drop, which became significant at 7 months of
age (P , .05). (B) Binary classification of APPPS1 and non-tg littermates based on CSF tau levels revealed a sensitivity and specificity of 55% and
92% for 1.5- and 3-month-old mice, respectively, and 100% for all the other age groups, assuming equal sensitivity and specificity. Arbitrary cutoff values
(pg tau/mL CSF) were chosen as indicated for each age group to achieve best discrimination between the two genotypes. (C) Total brain Ab levels (sum of
Abx–40 and Abx–42, i.e., the species ending at amino acid 40 and 42) were measured in the same tg mice and revealed a robust increase with aging [ANOVA:
F(4, 56) 5 2101, P , .001]. The Tukey post hoc test indicated a significant difference among all age groups (P , .001), except between 13 and 19 months.
(D) The relationship between CSF tau (A) and brain Ab concentration (C) is best described by a linear regression (r2 5 0.84, P , .001) indicating a strong
positive correlation (Spearman rank correlation test: r 5 0.94, P , .001). (E) The percentage increase of total brain Ab (green) and CSF tau (blue) in
APPPS1 mice shows a very similar profile with aging. The two curves are based on the mean values of panels (A) and (C). Data in (A) and (C) are presented
as group means 6 standard errors of mean.
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3 months of age (with 92% specificity and sensitivity); in the
older age groups, CSF tau concentrations allowed an unam-
biguous segregation of APPPS1 mice and non-tg littermates
(Fig. 1B).
As expected, Ab levels in the brains of APPPS1 mice re-
vealed a robust age-dependent increase (Fig. 1C) closely
paralleling the CSF tau increase (Fig. 1E). A significant pos-
itive correlation between brain Ab and CSF tau was
apparent, indicating that the CSF tau concentration reflects
the Ab pathology (Fig. 1D).
3.2. Ab pathology–associated tau increase in CSF is
impeded by prolonged BACE1 inhibition
To more directly demonstrate a causal relationship
between the stage of Ab pathology in brain and tau in
CSF, we tested if suppression of Ab pathology would
affect CSF tau concentrations. Therefore, we treated
1.5-month-old APPPS1 mice for 6 months with the BA-
CEi NB-360 [6] while littermates were fed with control
pellets (Fig. 2A). Ab immunohistochemistry revealed a
71% lower cortical Ab plaque load in the brains of
NB-360–treated mice compared with controls
(Fig. 2B). Consistently, brain Ab concentrations of NB-
360–treated mice revealed a very strong reduction in
comparison to mice fed with control food pellets and
were similar to those of the 1.5-month-old mice
(Fig. 2C). As anticipated from previous work [2], Ab42
significantly decreased with age in CSF of APPPS1
mice. However, NB-360 treatment did not further
decrease CSF Ab42 (Fig. 2D).
When CSF tau was analyzed using our newly developed
high-sensitivity tau sandwich immunoassay, we found the
Fig. 2. BACE1 inhibition in APPPS1 mice prevents tau increase in CSF. Male and female APPPS1 mice (1.5–7.5 months of age; 8–9 mice per group, gender
equally distributed, i.e., 4–5 males/females per group) were either fed with food pellets containing a BACE1 inhibitor NB-360 (BI) or control pellets (Ctrl) for
6 months (27 weeks). (A) Schematic overview of experimental design. Shown are representative cortical brain sections for each group (scale bar is 500 mm). (B,
C) Stereological quantification of neocortical Ab immunostaining (Ab load) and measurement of Ab levels in brain exhibited significant increases with age,
which could largely be blocked by BACE1 inhibition [analysis of variance (ANOVA) F(2, 22)5 114.6 and 209.5, respectively, P, .001; the Tukey post hoc test
**P , .01, ***P , .001]. (D) CSF Ab42 in the 7.5-month-old APPPS1 mice was significantly decreased compared with 1.5-month-old mice with no further
decrease after BACE1 inhibition [ANOVA: F(2, 22) 5 13.58, P 5 .0001; the Tukey post hoc test **P , .01, ***P , .001]. A similar result was found for
Ab40 (not shown). (E) Tau in CSF revealed a significant age-dependent increase in control mice, which could be prevented by the application of a BACEi [AN-
OVA: F(2, 22) 5 57.01, P , .001; the Tukey post hoc ***P , .001]. No gender effect was found in any of the measurements and males and females were
combined. All data are represented as group means 6 standard errors of mean.
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expected increase from 1.5 to 7.5 months of age in the
APPPS1 mice fed with the control pellets. In striking
contrast, CSF tau concentrations remained at baseline level
(levels at the time the treatment was started) in the NB-
360–treated APPPS1 mice (Fig. 2E).
To confirm these observations in a second mouse
model and to assess the effect of BACE1 inhibition in a
situation of preexisting Ab pathology, 15-month-old
APP23 mice were treated with the same BACEi until
the age of 21.5 months (Fig. 3A). Similar to APPPS1
mice, the increase in Ab plaque load and brain Ab levels
could be almost completely impeded (Fig. 3B and 3C).
Interestingly, in this mouse line, CSF Ab42 was signifi-
cantly reduced in NB-360–treated animals compared
with baseline and control mice (Fig. 3D), and remarkably,
NB-360 fully prevented the increase of CSF tau levels
also in APP23 mice (Fig. 3E).
3.3. CSF tau levels stay unaltered after short-term BACE1
inhibition
To test the possibility that the reduction of soluble Ab or
the BACEi itself could directly lead to a decline of CSF tau,
that is, in the absence of changes in Ab deposition, young
APPPS1 and APP23 mice were treated with NB-360–con-
taining food pellets for one week. After this acute treatment,
CSF Ab42 levels revealed a significant reduction demon-
strating the pharmacodynamic effect of the drug (Fig. 4A
and 4C). However, CSF tau levels remained unaffected by
the short-term treatment in both APPPS1 and APP23 mice
(Fig. 4B and 4D).
Fig. 3. BACE1 inhibition in APP23mice prevents tau increase in CSF.Male APP23mice (15–21.5months of age; 8–9mice per group) were either fed with food
pellets containing a BACE1 inhibitor NB-360 (BI) or control pellets (Ctrl) for 6.5 months (29 weeks). (A) Schematic overview of experimental design including
representative cortical brain sections for each group (scale bar is 500 mm). (B, C) Stereological quantification of cortical Ab immunostaining (Ab load) and
measurements of Ab levels in brain exhibited significant age-dependent increases, which could be completely blocked by BACE1 inhibition [ANOVA: F(2,
22) 5 52.61 and 81.58, P , .0001; the Tukey post hoc test ***P , .001]. (D) CSF Ab42 in the NB-360–treated mice was significantly decreased compared
with 15-month-old mice and age-matched controls [ANOVA: F(2, 22) 5 33.81, P , .0001; the Tukey post hoc test ***P , .001]. A similar result was found
for Ab40 (not shown). (E) CSF tau exhibited a significant age-dependent increase in control mice, which could be suppressed by the application of BACEi [AN-
OVA: F(2, 22) 5 31.85, P , .0001; the Tukey post hoc ***P , .001]. All data are represented as group means 6 standard errors of mean.
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4. Discussion
Tau is, besides Ab, the most thoroughly investigated and
validated CSF biomarker for AD [16–20] and hence has
already been implemented as a monitoring marker for
clinical trials [1]. Our previous observation of CSF
biomarker changes in aging APP tg mice suggests that tangle
formation and global neuron loss are not required to induce a
substantial tau rise in the CSF [2]. Instead, presumed
neuronal injury below the threshold of histological detection
caused by progressing cerebral Ab deposition was suggested
to trigger an increased release of tau from nerve cells, which
ultimately leads to elevated CSF tau levels. However,
proving such a mechanistic link between Ab deposition
and CSF tau changes requires a direct interference with
Ab aggregation and deposition.
To this end, we now treated two different APP tg mouse
models with a potent BACEi. Indeed, reducing Ab produc-
tion over 6 months not only attenuated Ab deposition but
also affected CSF tau levels. In both mouse models, long-
term BACE1 inhibition kept CSF tau at baseline levels,
whereas control mice revealed the expected age-related in-
crease. Thus, CSF tau levels mirrored the histological plaque
load and total brain Ab levels after BACEi treatment.
In further support of a mechanistic link between CSF tau
levels and brain Ab deposition is the observation that
BACE1 inhibition kept CSF tau at baseline but did not
reduce further to levels of wild type mice. This observation
indicates that the preexisting Ab plaques, which were obvi-
ously not cleared by long-term BACEi treatment, were
responsible for the elevated CSF tau levels. This is consistent
with the observation that short-term BACE1 inhibition and
thus soluble Ab had no effect on CSF tau levels (Fig. 4).
Although NB-360 is known to inhibit both BACE1 and
also BACE2 [6] with several substrates known for these sec-
retases [21], it seems unlikely that a substrate other than APP
would be responsible for the CSF tau changes given that
short-term BACEi treatment had no effect on CSF tau levels.
While our results demonstrate that CSF tau levels reflect
brain Ab deposits, they also suggest that CSF Ab42 may be
a misleading readout for brain Ab deposition in the context
of BACE1 inhibition because CSF Ab levels are affected
by two opposite mechanisms. On the one hand, BACE1 inhi-
bition directly reduces the generation of Ab and thus lowers
CSF Ab levels, which was also evident in the short-term
experiments in both mouse models (Fig. 4). On the other
hand, long-term BACE1 inhibition attenuates Ab deposition
that in turn leads to reduced Ab sequestration to plaques and
hence maintains CSF Ab42 at higher levels. These antago-
nistic mechanisms may also explain why in APP23, but not
in APPPS1 mice, CSF Ab42 concentrations were consider-
ably lower after BACE1 treatment compared with mice that
were fed with the control food pellets (Figs. 2D and 3D).
Differences in CSF Ab between APP23 and APPPS1 mice
after BACE1 inhibition may also be related to differences
in the Ab species generated in the two models, which may
affect the overall turnover of brain Ab, its aggregation/
sequestration to plaques, and the type of amyloid
deposited. Overall, these observations and results highlight
that CSF Ab42 may be a misleading readout in the context
of BACE1 inhibition as it is confounded by the stage (and
type) of amyloid deposition at the start of treatment. While
there are no data published regarding CSF tau changes in
clinical trials on BACE1 inhibition, it has been reported
that immunotherapy directed against Ab decreased CSF tau
levels in AD patients [22,23]. However, as no significant
difference in CSF Ab42 was found, the interpretation of
decreased tau CSF tau levels remained unclear at the time.
In conclusion, the present study demonstrates a mech-
anistic link between brain Ab deposition and CSF tau,
and thus, CSF tau may present an important readout of
Ab deposition in mouse models and likely in AD.
Furthermore, the effect of BACE1 inhibition is not
restricted to Ab and amyloid plaque deposition but can
positively influence other downstream pathologic events
underscoring the high potential of this target for the treat-
ment of AD.
Fig. 4. Short-term BACE1 inhibition does not affect CSF tau levels. Male
and female APPPS1 mice (2 months of age; 4 mice per group; gender
equally distributed, i.e., 2 males/females per group) and male APP23
mice (3 months of age; 6–7 mice per group) were either fed with food pel-
lets containing a BACE1 inhibitor NB-360 (BI) or control pellets (Ctrl) for
one week. (A) In APPPS1 mice, CSF Ab42 was reduced by 76% after NB-
360 application (t-test t6 5 4.134, **P , .01). (B) Treatment of APPPS1
mice with a NB-360 for one week did not reveal significant changes in
CSF tau levels (t-test t6 5 0.051, P . .05). (C) In APP23 mice, CSF
Ab42 was also significantly reduced after NB-360 treatment (t-test
t11 5 7.300, ***P , .001). (D) Again no significant difference could be
detected after BACE1 inhibition for 1 week (t-test t11 5 0.497,
P . .05). All data are represented as group means 6 standard errors of
mean.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the liter-
ature using PubMed. While there have been several
publications describing CSF tau changes in APP
transgenic mice and also direct effects of BACE1
inhibitors such as the reduction of Ab levels in
CSF and brain, there are no data published yet
regarding downstream effects of BACE1 inhibition
and a causal relationship between CSF tau and b-
amyloidosis. The relevant citations are appropri-
ately cited.
2. Interpretation: Our findings led to a validated hy-
pothesis describing CSF tau changes on BACE1 inhi-
bition. This hypothesis renders CSF tau a valuable
marker to predict the effectiveness of BACE1 inhib-
itors in current clinical trials.
3. Future directions: The manuscript proposes a frame-
work for the generation of new hypotheses and the
conduct of additional studies. Examples include
further understanding (a) the mechanistic link be-
tween CSF tau levels and brain Ab deposition and
(b) potential other downstream pathological events
caused by BACE1 inhibition.
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Supplemental Fig. 1. Tau assay development and validation. (A) From a set of different antitau antibodies, the 
most sensitive pair has been chosen for the full development of an assay on the Simoa platform. Both antibodies 
ADx202 (green) for capturing and 77E9 (orange) for detection bind to the proline-rich domain of tau, 
recognizing the epitope 218–225 and 185–195 (human sequence), respectively. The human (top) and the mouse 
(bottom) sequence are shown and differences indicated in red. Western blot analyses (12% Bis-Tris PAGE) 
using 10% (wt/vol) brain homogenates from a TauP301S (tg), Tau null (ko), and C57BL6/J wild-type (WT) 
mouse revealed some unspecific bands (at ∼98 and ∼38 kDa) with 77E9 but not with ADx202 (lower panel). (B) 
Average calibration curve based on four individual runs using recombinant murine tau on the Simoa technology. 
Shown are the mean signals ± SD, indicated as average enzymes per bead (AEBs), within a concentration range 
from 0.091 to 600 pg/mL. (C) Linear dilution analyses of pooled CSF from C57BL/6J wild-type mice showed 
115%, 107%, 101%, and 77% recovery of endogenous tau when diluted 20, 40, 80, and 160 times, respectively 
(the average of all recalculated concentrations was considered as the 100% reference value). Note: even a 160-
fold dilution yielded a recovery of 77% (CV = 23.7%) although tau concentration of 0,66 pg/mL was slightly 
below the lower limit of quantification (0.69 pg/mL). 
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In cerebral B-amyloidoses such as Alzheimer’s disease (AD), mis-
folded AB proteins can form proteopathic seeds that structurally cor-
rupt similar proteins, which in turn further perpetuate the seeding 
cascade1. AB seeds are thus self-propagating agents that are responsi-
ble for the initiation, progression and spreading of amyloidosis in the 
brain. Indeed, when young AB-precursor protein (APP) transgenic 
mice are inoculated with AB-rich brain extracts from AD patients 
or aged APP transgenic mice, cerebral B-amyloidosis is induced 
4–8 months post-inoculation2,3. The seeding agent in the brain 
extracts has been identified as AB aggregates ranging in size from 
small, soluble proteinase K (PK)-sensitive AB assemblies to larger PK-
resistant aggregates4. AB seeds are resistant to ex vivo inactivation by 
such treatments as boiling, drying and exposure to formaldehyde2,5,6, 
and thus share key characteristics with infectious prions7–9.
To shed light on the in vivo stability, durability and propagation 
of AB seeds, we inoculated APP null (App−/−), wild-type (WT) and 
APP23 transgenic mice with brain extracts of defined AB seeding 
activity (Online Methods). At 1, 7 and 30 d post unilateral inocula-
tion (dpi) into the hippocampus, the injected and contralateral hip-
pocampi were dissected and assessed for the presence of exogenous 
human AB by immunoblotting and immunoassay (Fig. 1a,b). At 1 dpi, 
the injected human AB was present in the injected hippocampi of 
all three murine strains at similar levels. Human AB decreased at 
7 dpi and was below the level of detection at 30 dpi in App−/− and 
WT mice with apparently similar kinetics. In contrast, human AB 
in APP23 mice increased steadily over the 30-d incubation period 
(Fig. 1a,b), indicative of a nascent seeding response.
To assess the seeding activity of hippocampal extracts from App−/− 
and APP23 mice that had been previously inoculated with AB seeds, 
we carried out second passage inoculations into young APP23 
host mice (Fig. 1c–e). After a 4-month incubation period, the 1 dpi 
hippocampal extracts from both App−/− and APP23 donor mice had 
induced amyloid deposition in APP23 host mice that was similar to 
the induction by 30-dpi hippocampal extracts from the APP23 mice 
(Fig. 1c,d). Notably, amyloid induction was still observed for the 
App−/− 30-dpi hippocampal extracts, even though it was minimal after 
4 months (Fig. 1c,d).
We previously found that the seeding of AB lesions is time 
dependent2,4. Sensitivity as measured in seeding units increased ten-
fold when the incubation period was prolonged from 4–6 months, 
and again tenfold following prolongation from 6–7 months (F.B., M.S. 
and M.J., unpublished observations). Indeed, when the incubation 
time of the second passage inoculation was prolonged to 8 months, 
substantial amyloid induction also was observed for the App−/−  
30-dpi hippocampal extracts, suggesting the persistence of some 
AB seeds for 30 d in the absence of host-derived AB (Fig. 1c,e).
Our findings were unexpected given that brain extracts from prion-
inoculated Prnp null mice no longer reveal infectivity 2 weeks post-
inoculation using observation periods of up to 16 months following 
secondary transmission10–12. We therefore repeated the experiment 
and included extended primary incubation periods in the App−/− donor 
mice of 60 and 180 d, as well as additional control inoculations of WT 
brain extracts (Fig. 2). Consistent with the first experiment, human 
AB levels were below detection in the extract-injected hippocampi of 
App−/− mice 30, 60 and 180 dpi using immunoblotting and electro-
chemiluminescence-linked (ECL) immunoassay. However, using 
ultra-sensitive bead-based single-molecule array Simoa technology, we 
were able to detect residual human AB even at 180 dpi (Supplementary 
Fig. 1). Second passage inoculation with an 8-month incubation time 
again revealed robust induction of B-amyloidosis in APP23 hosts by 
the App−/− 30-dpi hippocampal extracts, whereas no induction was 
observed with the WT extracts (Fig. 2a,b). Amyloid induction was also 
observed with the App−/− 60-dpi hippocampal extract, albeit some-
what less than the App−/− 30-dpi extracts. Notably, even 180 d after the 
introduction of AB seeds, some amyloid induction was instigated by 
hippocampal extracts from App−/− donor mice (Fig. 2a–c).
In all cases, the induced lesions were partly Congo red positive. 
All Congo red–positive amyloid (independent of whether the 
primary incubation occurred in App−/− or APP23 hosts) was sur-
rounded by activated microglia and dystrophic neuritic structures 
(Supplementary Fig. 2), as previously reported in the brains of AD 
patients and APP transgenic mice13–16. Notably, cerebral amyloid 
angiopathy (CAA) was always induced together with parenchymal 
amyloid (Supplementary Fig. 3) and appeared in non-injected brain 
regions, most notably in the thalamus, similar to the pattern previously 
observed after primary inoculations2. The induced CAA was often 
associated with microbleeds (Supplementary Fig. 3), supporting the 
Persistence of AB seeds in APP 
null mouse brain
Lan Ye1–3,5, Sarah K Fritschi1,2,5, Juliane Schelle1–3,  
Ulrike Obermüller1,2, Karoline Degenhardt1–3, Stephan A Kaeser1,2, 
Yvonne S Eisele1,2, Lary C Walker4, Frank Baumann1,2,  
Matthias Staufenbiel1,2 & Mathias Jucker1,2
Cerebral B-amyloidosis is induced by inoculation of AB seeds 
into APP transgenic mice, but not into App−/− (APP null) 
mice. We found that brain extracts from APP null mice that 
had been inoculated with AB seeds up to 6 months previously 
still induced B-amyloidosis in APP transgenic hosts following 
secondary transmission. Thus, AB seeds can persist in the 
brain for months, and they regain propagative and pathogenic 
activity in the presence of host AB.
1Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. 2German Center for Neurodegenerative 
Diseases (DZNE), Tübingen, Tübingen, Germany. 3Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, Tübingen, Germany.  
4Yerkes National Primate Research Center and Department of Neurology, Emory University, Atlanta, Georgia, USA. 5These authors contributed equally to this work. 
Correspondence should be addressed to M.J. (mathias.jucker@uni-tuebingen.de).
Received 16 July; accepted 25 August; published online 9 September 2015; doi:10.1038/nn.4117
	   68	  
©
20
15
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
2 ADVANCE ONLINE PUBLICATION NATURE NEUROSCIENCE
B R I E F  COM M U N I C AT I O N S
conclusion that the exogenous AB seeds retained their pathogenicity 
in App−/− donor mice, even in the absence of replication.
Our results demonstrate a marked longevity of AB seeding activity in 
the living brain despite generally efficacious AB clearance mechanisms. 
The persistence of AB seeding activity for at least 180 d in the brain 
in the absence of host-derived AB (and thus replication) substantially 
exceeds the reported longevity of bioactive prions, at least with regard 
to prion infectivity in mice10–12,17. In conjunction with previous stud-
ies demonstrating the resilience of AB seeds2–6, this observation raises 
the possibility that a similar phenomenon transpires in AD and other 
human disorders. AD per se has not been shown to be infectious under 
normal circumstances. However, cerebral AB deposition is inducible by 
injection of exogenous AB seeds in a prion-like manner in transgenic 
mice and nonhuman primates1,9. In this regard, it may be prudent 
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Figure 1 AB seed persistence in various  
murine hosts. AB seed–containing APP23  
brain extract (APPtg extract) was injected  
unilaterally into the hippocampus of  
3-month-old male and female App−/−,  
WT and APP23 mice. Injected and  
contralateral control hippocampi were  
biochemically analyzed 1, 7 and 30 dpi.  
(a) Immunoblots with an antibody  
specific to human AB. Although the injected  
AB could be detected 1 dpi in App−/−,  
WT and APP23 mice, the injected AB  
was no longer detectable at 30 dpi in  
App−/− or WT mice (left and middle).  
The injected hippocampus is marked  
with + and the uninjected side with −.  
In contrast, human AB was still robustly  
increased compared with the uninjected  
side in APP23 mice at 30 dpi (right).  
Shown is one representative mouse for  
1 dpi and two mice for 7 and 30 dpi,  
respectively. Bottom, GAPDH as a loading  
control. Synthetic (syn) AB (0.23 ng) was  
loaded as a positive control. (b) Human  
AB concentration (pg ml−1) in the extracted  
hippocampus using ECL-linked immunoassay.  
Although human AB in the inoculated  
hippocampus of App−/− and WT mice was  
significantly decreased to background (–)  
at 30 dpi (left and middle), APP23 mice  
did not show such a reduction (right)  
(n = 6, 4–5 and 7–8 mice per time point  
for App−/−, WT and APP23 mice, respectively;  
males and females were equally distributed  
in each group). One-way ANOVA for the  
injected hippocampi revealed F(2,15) = 5.603,  
P = 0.015 (App−/−); F(2,10) = 8.484,  
P = 0.007 (WT); F(2,20) = 1.162,  
P = 0.333 (APP23). Bonferroni post hoc  
test for pairwise comparisons, *P < 0.05,  
**P < 0.01. (c) Secondary transmission of  
injected hippocampal extracts (hippocampi  
were pooled) from App−/− and APP23 mice  
(1 and 30 dpi) into the hippocampus of  
young (3 month old) pre-depositing male  
APP23 mice. Brains were analyzed for  
AB deposition 4 and 8 months later. Shown  
are combined AB-immunostained and Congo  
red–stained hippocampi. Hippocampal  
1-dpi extracts from both App−/− (left) and  
APP23 mice (right) induced AB deposition  
after the 4-month incubation period,  
and considerably more deposition after  
8 months. Consistent with the immunoassays,  
the 30-dpi APP23 extracts also induced  
robust seeding activity. Notably, hippocampal  
extracts from the 30-dpi App−/− mice also  
displayed seeding activity (barely detectable  
after the 4-month incubation period but robustly present after 8 months). Scale bars represent 100 Mm. (d,e) Stereological quantification of 
hippocampal AB immunostaining (AB load). Indicated is the mean o s.e.m. Kruskal-Wallis test for the 4-month incubation: P = 0.026, n = 3 mice per 
group; for the 8-month incubation: P = 0.032, n = 4–5 mice per group; Mann-Whitney test with Bonferroni correction, *P a 0.05.
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to consider more stringent measures to mitigate the transmission 
of AB seeds by such means as contaminated surgical instruments or 
biologics1. To this end, the murine AB-seeding model is an exquisitely 
sensitive bioassay for the presence and functionality of AB seeds.
The extreme longevity of AB seeds in vivo also provides new 
insights into the long, clinically silent period that precedes the onset 
of dementia in AD18,19. Current estimates, based on the assessment 
of AB by positron emission tomography imaging and cerebrospinal 
fluid measurements, indicate that preclinical AD begins approxi-
mately 20 years before the first clear signs of incipient dementia18,19 
and is characterized by the progressive appearance of cerebral AB 
deposits in neocortical areas with subsequent spreading to other 
parts of the brain20. The discovery that AB seeds can exist in the 
brain at levels below routine detection indicates that the initial 
changes that drive AD pathogenesis may occur even earlier. From a 
therapeutic standpoint, these findings indicate that the most effec-
tive treatments for AD should target the AB cascade well before the 
characteristic deposits of AB become detectable by currently available 
methods. However, our findings in WT mice and App−/− mice also 
indicate that impeding the production of AB will inhibit the generation 
of new seeds and thereby delay or prevent the onset of dementia.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Figure 2 AB seed persistence in App−/− mice for 
up to 6 months. (a) AB seed–containing APP23 
brain extract (APPtg extract) or WT mouse 
brain extract was injected bilaterally into the 
hippocampus of 3-month-old male App−/− mice. 
The injected hippocampi were isolated 30, 60 
or 180 dpi (n = 4–5 mice per group), pooled 
and used for secondary transmission into the 
hippocampus of young, 3-month-old APP23 
mice. Brains were analyzed for AB deposition  
8 months later. Shown is the AB-immunostained 
and Congo red–stained hippocampus. 
Consistent with the first experiment (Fig. 1), 
30-dpi App−/− hippocampal extracts induced 
robust AB deposition, whereas no amyloid 
deposition was observed with the WT extract.  
To our surprise, the 60-dpi App−/− extract 
and even the 180-pi App−/− extract induced 
some amyloid deposition. Scale bar represents 
100 Mm. (b) Stereological quantification of 
hippocampal AB immunostaining (AB load). 
Indicated is the mean o s.e.m. WT and APPtg 
extract 30 dpi, n = 2 mice each (but see  
Fig. 1); APPtg extract 60 and 180 dpi, n = 4  
and n = 3 mice per group, respectively.  
(c) Diminished induction of AB deposition by 
App−/− hippocampal extracts with increasing dpi 
(animals from this experiment are combined in 
this graph with the 1- and 30-dpi animals from 
Fig. 1e). One-way ANOVA revealed F(3,14) = 
15.210, P = 0.0001; Bonferroni post hoc test for 
pairwise comparisons, **P < 0.01, ***P < 0.001.
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Mice. For all inoculations 3–4-month-old C57BL/6J-Tg(Thy1-APPK670N;M671L)23 
mice (APP23 mice), C57BL/6J (WT), and C57BL/6J-App (App−/−)21,22 mice were 
used. All mice were kept under specific pathogen-free conditions. The experi-
mental procedures were carried out in accordance with the veterinary office 
regulations of Baden-Württemberg (Germany) and approved by the local Animal 
Care and Use Committees (Regierungspräsidium Tübingen).
Preparation of brain tissue extracts for intracerebral inoculation. We used 
extraction protocols as previously described2,3. Tissue for extract preparation was 
derived from aged (24.5–26.0 month old) amyloid-depositing male APP23 trans-
genic mice containing approximately 400,000 ID50 units per ml of seeding agent 
as estimated by serial dilutions (Ye, L., Kaeser, S.A., Marzeso, A., Obermüller, U., 
Odenthal, J., Fritschi, S.K., Staufenbiel, M., Baumann, F. & Jucker, M., unpub-
lished observations), and from age-matched non-transgenic WT mice. After 
removal of the cerebellum and lower brainstem, forebrain samples were imme-
diately fresh-frozen on dry ice and stored at −80 °C until use. Tissue was then 
homogenized (Ultra Turrax T8, IKA-Werke) at 10% (wt/vol) in sterile phosphate-
buffered saline (PBS, Lonza), vortexed, sonicated 3 × 5 s (LabSonic, B. Braun 
Biotech International GmbH, 0.5 mm diameter sonotrode, cycle 1, amplitude 
80%) and centrifuged at 3000g for 5 min to remove tissue debris. The supernatant 
was aliquoted and stored at −80 °C until use. Different extracts were used for 
the experiments described in Figures 1 and 2. The amount of AB in the APP23 
extracts was ~10 ng Ml−1, similar to previous publications2,3.
Intrahippocampal inoculation. Stereotactic injections were made under a mix-
ture of ketamine/xylazine in PBS (ketamine 118 mg per kg of body weight, xyla-
zine 8 mg per kg). Inoculates were stereotactically placed with a Hamilton syringe 
into the hippocampus (unilateral: AP −2.5 mm, L −2.0 mm, DV −1.8 mm, bilat-
eral: AP −2.5 mm, L o 2.0 mm, DV −1.8 mm,). 2.5 Ml were injected at the speed 
of 1.25 Ml min−1 and the needle was kept at the injection site for an additional 
2 min before withdrawal. The surgical area was cleaned with sterile PBS and the 
incision was sutured. Postoperatively, the mice were maintained under infrared 
light and monitored until they had recovered from the anesthesia.
Preparation of hippocampal extracts from primary inoculation. Hippocampi 
from inoculated App−/−, WT and APP23 mice were dissected 1, 7, 30, 60 and 
180 dpi. Each hippocampus was immediately fresh-frozen on dry ice and stored 
at −80 °C until use. Tissue was then homogenized at 10% (wt/vol) in PBS using a 
1 ml BD Plastikpak syringe (Becton Dickson). Homogenate was then vortexed, 
sonicated 3 × 5 s and centrifuged at 3000g for 5 min. The supernatant was aliq-
uoted and immediately frozen at −80 °C until use. Hippocampal extracts from the 
primary inoculation in each group were pooled for secondary inoculation.
Quantification of AB by immunoassays. Hippocampal extracts were pretreated 
with formic acid (Sigma-Aldrich, final concentration: 70%, vol/vol), sonicated for 30 s 
on ice and centrifuged at 25,000g for 1 h at 4 °C. Supernatants were equilibrated 
in neutralization buffer (1 M Tris base, 0.5 M Na2HPO4, 0.05% NaN3 (wt/vol)). 
Human AB was measured either by an electrochemiluminescence (ECL)-linked 
immunoassay (Meso Scale Discovery, MSD), as previously described4,23, or by an 
ultra-sensitive bead-based single molecule array (Simoa, Quanterix). All samples 
and calibrators were run in duplicates. For the MSD platform commercial Human 
(6E10) Abeta Triplex Assay was used according to the manufacturer’s instruc-
tions. In brief, 96-well plates pre-spotted with C-terminal capture antibodies 
against ABx-38, ABx-40 and ABx-42 were blocked for 1 h with 1% bovine serum 
albumin (BSA in Tris buffer, wt/vol) and washed three times with Tris buffer. 
Formic acid–treated samples were co-incubated with the SULFO-TAG 6E10 
detection antibody solution on the plate for 2 h. After washing, MSD Read Buffer 
T was added and the plate was measured immediately on the Sector Imager 6000. 
Data analysis used MSD DISCOVERY WORKBENCH software 2.0. Internal QC 
samples were used for quality control of the assay performance and inter-plate 
variability. Total AB was the sum of ABx-38, ABx-40 and ABx-42.
Samples with very low AB levels were also measured using the commercial 
Simoa Human AB40 and Human AB42 kits from Quanterix. Depending on 
the expected AB concentration formic acid treated samples were diluted 
(at least 1:2) in sample diluent before being subjected to the fully automated 
analysis. AB was captured by antibody-coated beads and co-incubated with 
biotinylated detector antibodies against AB40 (or AB42) to form a complex. 
After a wash step, a streptavidin-B-galactosidase (SBG) conjugate was added and 
after further washing, resuspension in a substrate solution led to a fluorescence 
signal in the presence of SBG. Following transfer to the array disc, beads were 
individually sealed in microwells and quantified by the optical system of the 
Simoa HD-1 Analyzer. Each labeled AB molecule yielded a measurable signal. 
For the calibration, the software uses a Cubic (1/Y2 with zero point custom 
weight of 0.1) or a 4 Parameter Logistic (1/Y2 weighted) curve fit data reduction 
method for the human AB40 and AB42 assays, respectively. For internal quality 
control, 3 in-house QC samples (at high, intermediate, and low AB concentra-
tion) were measured in each individual run. Total AB was the sum of AB40 
and AB42.
Immunohistochemistry and histology. Mice were deeply anesthetized with 
ketamine (300 mg per kg)/xylazine (20 mg per kg), transcardially perfused with 
ice-cold PBS (8 min) and decapitated. Brains were removed, immersion-fixed 
for 48 h in 4% paraformaldehyde in PBS (wt/vol), cryoprotected in 30% sucrose 
(wt/vol) in PBS for an additional 48 h, and then frozen in 2-methylbutane. Fixed-
frozen brains were cut into 25 Mm-thick coronal sections and collected in cryo-
protectant buffer (35% ethylene glycol, 25% glycerol in PBS, vol/vol). Sections 
were stored at −20 °C until use. Immunohistochemistry was performed according 
to standard protocols with the Vectastain Elite ABC Kit (Vector Laboratories). 
As primary antibody, polyclonal rabbit AB-antibody NT12 and polyclonal rabbit 
anti-ionized calcium binding adaptor molecule 1 (Iba1, Wako Chemicals) were 
used as previously described2. In addition rabbit polyclonal antibody 5313 to 
the ectodomain of APP (generous gift of C. Haass, Munich) was used. Staining 
with Congo red for amyloid or Perl’s Prussian blue for ferric iron was conducted 
according to standard protocols.
Quantification of total Ab load. AB load was quantified on AB-immunostained 
sets of every 12th systematically sampled, serial, coronal section throughout the 
entire hippocampus. Researchers who performed the analysis were blinded to 
the inoculation groups. Stereological analysis was performed using a microscope 
equipped with a motorized x-y-z stage coupled to a video-microscopy system 
and the Stereo Investigator software (MicroBrightField) as previously described2. 
Total AB load was determined by calculating the % areal fraction occupied by 
AB-positive staining in two-dimensional sectors at a single focal plane (20×, 
0.45 NA objective).
SDS-PAGE and immunoblot analysis. Hippocampal extracts were analyzed on 
NuPage Bis-Tris mini gels using NuPage LDS sample buffer and MES running 
buffer (Invitrogen). Proteins were transferred onto a nitrocellulose membrane, 
probed with monoclonal antibody 6E10 specific to human AB (Covance) and 
visualized using Amersham ECL Plus (GE Healthcare).
Statistics. Data in figures are expressed as mean o s.e.m. Statistical analysis was 
performed using the GraphPad Prism software, version 6.0. The Kolmogorov-
Smirnov test was used to assess the normality of the data distribution. Depending 
on the outcome of the Kolmogorov-Smirnov test, one-way ANOVA followed by 
the Bonferroni post hoc test or the Kruskal-Wallis test followed by the Mann-
Whitney test with Bonferroni correction were used.
A Supplementary MethodT Checklist is available.
21. Calhoun, M.E. et al. Proc. Natl. Acad. Sci. USA 96, 14088–14093 (1999).
22. Eisele, Y.S. et al. J. Neurosci. 34, 10264–10273 (2014).
23. Maia, L.F. et al. Sci. Transl. Med. 5, 194re192 (2013).
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Supplementary Figure 1 
Ultra-sensitive bead-based Simoa technology detects residual human Aβ in hippocampal extracts of inoculated App−/− mice. 
Aβ seed-containing APP23 brain extract or seed-negative WT mouse brain extract was injected into the hippocampus of App−/− mice. 
The injected hippocampi were isolated 1, 30, 60, or 180 dpi (see Figures 1 and 2). While ECL-linked immunoassay no longer detected 
any Aβ at and beyond 30 dpi (Figure 1), the bead-based Simoa technology detected human Aβ up to 180 dpi. Note that the majority of
Aβ was cleared within the first 30d with much slower clearance of residual Aβ thereafter. (The same samples were analysed as in 
Figures 1 and 2, thus n=6, 10, 5, and 5 for 1d, 30d, 60d, and 180d, respectively). One-way ANOVA for the APP transgenic extracts 
revealed F(3,22)=8.932, P=0.0007. Bonferroni post hoc test for pairwise comparisons, **P<0.01, ***P<0.001. WT-injected mice (n=4; 
30 or 60 dpi). 
Nature Neuroscience: doi:10.1038/nn.4117
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Supplementary Figure 2 
Induced amyloid lesions are partly congophilic and surrounded by activated microglia and dystrophic boutons. 
(a) Congo red-positive amyloid deposits induced in the dentate gyrus were surrounded by Iba1-positive microglia (black). (b) Congo 
red-positive plaque with surrounding hypertrophic microglial cell bodies and processes at higher magnification. (c) APP-immunoreactive 
dystrophic processes and boutons (black) in close proximity to a congophilic amyloid plaque. Images are from a 1 or 30 dpi App−/−
hippocampal extract-inoculated APP23 mouse.  Scale bar: 100μm (a), 20 μm (b,c). 
Nature Neuroscience: doi:10.1038/nn.4117
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Supplementary Figure 3 
Cerebral amyloid angiopathy (CAA) was always induced in addition to parenchymal amyloid. 
(a) Shown are the Aβ-immunostained and Congo red-stained hippocampus and thalamus of an 
APP23 mouse that had been inoculated with a 30 dpi App−/− hippocampal extract 8 months earlier. 
Note the prominent CAA in the thalamus (asterisk). Scale bar: 200 μm. (b) Perl´s Prussian blue 
staining of an adjacent section reveals multiple microhemorrhages in the CAA-laden thalamic region 
(arrow). Insert shows the microhemorrhages at higher magnification. Scale bars: 200 μm and (inset) 
50 μm. 
 
Nature Neuroscience: doi:10.1038/nn.4117
	   74	  
	  
 
 
3.4 Prevention of cerebral β-amyloidosis by targeting initial Aβ seeds 
 
 
 
Juliane Schelle, Sarah K. Fritschi, Ulrike Obermüller, Lisa M. Häsler, Marius Lambert, 
Stephan A. Kaeser, Ulf Neumann, Derya R. Shimshek, Matthias Staufenbiel, Mathias Jucker 
 
 
 
Manuscript in preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   75	  
Prevention of cerebral β-amyloidosis by targeting initial Aβ seeds 
 
 
Juliane Schelle1,2,3, Sarah K. Fritschi1,2,3, Ulrike Obermüller1,2, Lisa M. Häsler1,2,4, Marius 
Lambert1,2, Stephan A. Kaeser1,2, Ulf Neumann5, Derya R. Shimshek5, Matthias Staufenbiel1, 
Mathias Jucker1,2 
 
 
1Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University 
of Tübingen, 72076 Tübingen, Germany; 2DZNE, German Center for Neurodegenerative 
Diseases, 72076 Tübingen, Germany; 3Graduate School of Cellular and Molecular 
Neuroscience, University of Tübingen, 72074 Tübingen, Germany;  4Natural and Medical 
Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany; 5Novartis 
Institutes for BioMedical Research, Neuroscience, 4056 Basel, Switzerland 
 
 
 
 
 
 
 
 
 
Number of words: 216 (abstract); 6500 (total, including all) 
Figures: 6 
 
Correspondence: Mathias Jucker, mathias.jucker@uni-tuebingen.de. 
 
Key words: Alzheimer’s disease, Aβ seeds, preventive therapy, BACE inhibitor, anti-Aβ 
immunization  
 
 
 
	   76	  
ABSTRACT 
 
The insight that Alzheimer’s disease (AD) pathogenesis precedes dementia symptoms by 10-
20 years suggests that therapeutic compounds are most effective when applied at a pre-
clinical disease stage before neurodegeneration has become apparent. As the aggregation of 
the β-amyloid (Aβ) peptide is assumed to initiate the pathological process of the disease, 
therapeutical approaches for AD have been focused on anti-Aβ strategies. Amyloid 
deposition as an early event in AD pathogenesis together with the nucleated-dependent Aβ 
aggregation seen in vitro suggest a slow pre-amyloid lag phase in which Aβ seeds are 
presumably formed. Therefore a preventive therapy based on the interference with Aβ seed 
formation has the potential to show clinical efficacy in AD. Hence, in this study we treated 
two different APP transgenic mouse models at the beginning of plaque deposition with an Aβ 
specific antibody targeting Aβ seeds and a potent BACE inhibitor to lower Aβ production. 
We demonstrate that the short but early combination approach not only reduced brain Aβ 
levels acutely but also significantly decreased amyloid deposition even after discontinuation 
of the treatment for several months. Thus, targeting initial Aβ seeds at an early pre-amyloid 
stage by anti-Aβ immunization and BACE inhibition might be an effective and promising 
paradigm in order to delay or even prevent the development of cerebral β-amyloidosis and 
eventually AD. 
 
 
INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide and the 
leading cause of late-life dementia. However, so far no treatments are available to 
significantly slow down or stop AD. Recent studies have shown that AD pathogenesis starts 
10-20 years before the onset of first clinical symptoms (Villemagne et al. 2013; Bateman et 
al. 2012; Buchhave et al. 2012; Jack et al. 2010). Hence, the failure of previous clinical trials 
for AD can be explained by the fact that they were initiated in symptomatic patients, in which 
massive amyloid deposition and neurodegeneration have already begun and progressed for 
many years inducing a clinical phenotype (Selkoe 2012; Golde et al. 2011). Eventually the 
efficacy and safety of therapeutic compounds can be increased when given at a pre-clinical 
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disease stage before regular brain function is affected and irreversible damage has occurred 
(Bateman et al. 2012; Golde et al. 2011). 
According to the amyloid hypothesis and multiple genetic and biochemical evidences 
aggregation of the amyloid β (Aβ) peptide is suggested to be the first and initial lesion in AD 
brain (Selkoe & Hardy 2016; Holtzman et al. 2011; De Strooper 2010; Hardy & Selkoe 
2002). Given that Aβ accumulation is a key trigger of the disease, targeting Aβ seems to be a 
very reasonable therapeutical approach (Golde et al. 2010).  
From in vitro studies it is known that Aβ can form amyloid fibrils by a highly concentration-
dependent nucleated polymerization process. After a certain lag phase and a series of 
intermediate states an initial nucleus (Aβ seed) is formed. This so called slow nucleation 
phase is subsequently followed by a phase of exponential increase of Aβ aggregation and 
fibril formation due to addition of soluble Aβ to Aβ seeds by conformational conversion 
(Jucker & Walker 2013; Eisenberg & Jucker 2012; Chiti & Dobson 2006; Harper & 
Lansbury 1997). With increasing size the growing fibrils break and form new self-
propagating fragments and Aβ seeds (Jucker & Walker 2013). The lag time of amyloid 
formation in vitro can be shortened by the addition of small amounts of Aβ seeds (Harper & 
Lansbury 1997). 
These in vitro observations of Aβ amyloid formation have recently been translated in vivo by 
the demonstration that Aβ aggregation can be induced and accelerated in young, pre-
depositing APP transgenic (tg) mice by intracerebral injections of brain extract containing Aβ 
seeds (Meyer-Luehmann et al. 2006; Kane et al. 2000). Similar to in vitro assays the in vivo 
induction of Aβ deposition is dependent on the concentration of the Aβ seeds as well as the 
availability of soluble Aβ to be incorporated into the growing Aβ aggregates (Jucker & 
Walker 2013; Hamaguchi et al. 2012; Jucker & Walker 2011; Meyer-Luehmann et al. 2006).  
Aβ specific antibodies applied at early stages of plaque formation are intended to bind and 
inactivate already existing microplaques and therefore promote clearance of Aβ seeds. As the 
β-site of APP cleaving enzyme (BACE) initiates the production of the Aβ peptide it seems to 
be another attractive therapeutic target (Golde et al. 2011; Citron 2010; De Strooper et al. 
2010). Therefore an early intervention using a combinational treatment based on Aβ 
vaccination to remove pre-existing Aβ aggregates and a BACE inhibitor to block the 
processing of APP and thereby reduce the production of soluble Aβ may effectively delay or 
prevent cerebral β-amyloidosis. 
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In this study such a combined therapy based on an anti-Aβ specific immunization strategy 
together with a BACE inhibitor was used during a defined pre-depositing stage targeting first 
endogenous Aβ seeds in two different APP tg mouse models. This short and early 
intervention of initial Aβ aggregation delayed the onset of Aβ plaque pathology even after 
discontinuation of the treatment. Our findings suggest that targeting amyloid seeds at a pre-
amyloid stage and thereby interfering with the initial seeding phase of amyloid formation by 
immunotherapy and BACE inhibition is an effective therapeutic strategy to prevent cerebral 
β-amyloidosis and eventually AD. 
 
 
METHODS 
 
APP23 mice 
Male 6-month-old heterozygous APP23 mice (Sturchler-Pierrat et al. 1997) were all bred at 
the Hertie-Institute for Clinical Brain Research. APP23 mice express the K670M/N671L 
mutated human APP (Swedish double mutation) under control of the neuron-specific Thy1 
promoter element at about 7-fold over endogenous (murine) APP. The mice were generated 
on a B6D2 background but have since been bred with C57BL/6J mice over more than 20 
generations. In APP23 mice plaque formation starts at 6–8 months of age with a faster plaque 
development in females than in males (Eisele et al. 2010; Sturchler-Pierrat et al. 1997). 
Therefore only male animals were used for this study. While single male mice enjoyed 
housing enrichment, cages with several male mice were not provided with additional 
enrichment material due to possessive behavior. Mice were kept under specific pathogen-free 
conditions. All experimental procedures were conducted in accordance with veterinary office 
regulations of Baden-Württemberg (Germany) and approved by the local Animal Care and 
Use Committees.   
 
APP51 mice 
Male and female 12-month-old heterozygous APP51 mice (Bodendorf et al. 2002) were bred 
at the Hertie-Institute for Clinical Brain Research. APP51 mice express the human wild-type 
APP under control of the neuron-specific Thy1 promoter element at about 7-fold over 
endogenous (murine) APP and were bred on a C57BL/6J background. APP51 mice develop 
the first plaques between 13 and 15 months of age. Aβ plaque development is faster in 
females than in males. Therefore experiments were always conducted in mice of the same sex 
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(Figure 5 females, Figure 6 males). While female mice and single male mice enjoyed housing 
enrichment, cages with several male mice were not provided with additional enrichment 
material due to possessive behavior. Mice were kept under specific pathogen-free conditions. 
All experimental procedures were carried out in compliance with veterinary office 
regulations of Baden-Württemberg (Germany) and approved by the local Animal Care and 
Use Committees.   
 
Stereotactic injection of brain extract 
For intracerebral injections, 10% brain homogenates (without cerebellum) in sterile 
phosphate-buffered saline (PBS, Lonza) derived from β-amyloid-depositing APP23 mice (25-
26.0 month-old) were vortexed, sonicated 3 x 5 seconds (LabSonic, B. Braun Biotech 
International GmbH, 0.5 mm diameter sonotrode, cycle 1, amplitude 80%), and centrifuged at 
3,000 x g for 5 min. The supernatant (brain extract) was collected and stored at −80 °C until 
use. Host mice were 3- to 4-month-old female APP23 mice (n=3-6 per group). The mice were 
anaesthetized with a mixture of ketamine (100 mg/kg body weight) and xylazine (10 mg/kg 
body weight) in saline. 2.5 µl brain extract were bilaterally injected into the hippocampus 
(AP -2.5 mm, L +/-2.0 mm, DV -1.8 mm) with a Hamilton syringe. Injections were 
performed at 1.25 µl/minutes, and the needle was kept in place for additional 2 minutes 
before being slowly withdrawn. The surgical area was cleaned with sterile PBS, the incision 
was sutured, and the mice were maintained under infrared light and monitored until recovery 
from anesthesia.  
 
Passive Aβ  immunization  
APP23 mice inoculated with Aβ seeds containing brain extract, 6-months-old male APP23, 
and 12-months-old female APP51 mice were immunized intraperitoneally (i.p.) with 0.5 mg 
mouse monoclonal immunoglobulin IgG2a antibody Beta-1 (β1) or a control IgG2a antibody 
(anti-wheat germ agglutinin) once daily for five consecutive days. 12-months-old male 
APP51 mice were injected i.p. with 2 mg β1 or control antibody five times once a week. The 
β1 antibody recognizes amino acids 3-6 of human Aβ and has been shown to be effective in 
vivo in a passive immunization paradigm (Meyer-Luehmann et al. 2006; Pfeifer et al. 2002). 
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BACE inhibitor treatment  
6-month-old male APP23 mice (Figure 3 and 4) as well as 12-month-old female (Figure 5) 
and male (Figure 6) APP51 mice were fed with food pellets containing the BACE inhibitor 
NB-360 (0,5 g inhibitor / kg food pellets; Novartis, Basel, Switzerland (Schelle et al., 2017; 
Shimshek et al. 2016; Bacioglu et al. 2016; Neumann et al. 2015) for six weeks, respectively. 
Age-matched control mice received control pellets without the drug for the same time period. 
For the short-term experiments (Figure 3 and 5), NB-360-containing food pellets were 
replaced by control pellets three days before preparation except for groups 3 and 4 in Figure 
3 that received NB-360-containing food pellets until preparation. Food pellets were available 
ad libitum until the day of preparation. 
 
Brain tissue harvesting 
Mice were anesthetized with ketamine (100 mg/kg body weight) and xylazine (10 mg/ml) 
and sacrificed by transcardial perfusion with ice-cold PBS. Brains were removed and one 
hemisphere was snap-frozen on dry ice and stored at -80 ºC until use. The other hemisphere 
was immersion-fixed in 4% paraformaldehyde in PBS, pH 7.6, at 4 ºC for 48 hours, 
cryoprotected in 30% sucrose in PBS at 4 ºC for additional 48 hours, frozen in 2-
methylbutane, and stored at -80 ºC until use. 
 
Brain tissue homogenization and extraction 
Forebrains (hemispheres without cerebellum) from APP23 and APP51 mice were 
homogenized at 10% (w/v) in PBS or homogenization buffer (50 mM Tris pH 8.0, 150 mM 
NaCl, 5 mM EDTA and protease/phosphatase inhibitor cocktail from Thermo Scientific) 
twice at 5500 rpm and 4 °C for 10 sec using 7 ml lysing tubes with 2.8 mm ceramic beads 
and a tissue homogenizer (Precellys Bertin, Montigny-le-Bretonneux, France). The 
homogenized brain tissue was aliquoted and stored at -80 ºC until use. 
For Aβ measurements the brain homogenates were either extracted using formic acid (FA) or 
measured directly after centrifugation. For the FA-extraction aliquots were thawed on ice, 
mixed 1:3.2 with cold FA (min. 96% purity, Sigma, St. Louis, MO, USA), sonicated on ice 
for 35 seconds, and spun at 25,000 x g at 4 °C for one hour. The supernatant was collected as 
the “FA-soluble fraction” and equilibrated (1:20) in neutralization buffer (1M Tris base, 
0.5M Na2HPO4, 0.05% NaN3). For direct measurement (grey bars in Figure 2) aliquots were 
thawed on ice and spun at 25,000 x g at 4 °C for one hour. Supernatant was pipetted into a 
new tube and used for the measurement. 
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Ultrasensitive sandwich immunoassay for Aβ  measurements in brain extracts of pre-
depositing mice 
Aβ40 and Aβ42 concentrations in brain extracts from 1-8 month-old APP23 mice (Figure 2) 
were determined with an ultrasensitive bead based immunoassay using the human Aβ40 and 
human Aβ42 assay on the Simoa platform (Quanterix, Lexington, MA, USA). FA-soluble 
brain extracts were diluted 1:16 in sample diluent (Quanterix) for measurement of Aβ40 and 
1:4 for Aβ42 measurements. 25.000 x g supernatants of total brain extracts were diluted 1:64 
for direct measurements of Aβ40 and 1:32 for direct measurements of Aβ42 in the same 
buffer. FA-soluble total brain extracts from APP knockout and wildtype mice served as 
samples for testing specificity and were diluted 1:2 in Aβ40 and Aβ42 sample diluent for 
measurement of Aβ40 and Aβ42, respectively. Samples were measured on a Simoa HD-1 
Analyzer (Quanterix) using the provided assay protocol for human Aβ40 and human Aβ42 
assay. Data analysis was done using the Simoa software (Quanterix). Aβ40 and Aβ42 control 
samples in the low, mid, and high assay range served as a control and were measured in every 
Aβ40 and Aβ42 assay respectively. 
 
Aβ  measurement in brain extracts of depositing mice 
Aβ40 (Aβx-40) and Aβ42 (Aβx-42) concentrations in brain extracts from APP tg mice were 
determined with an electrochemiluminescence-linked immunoassay using the V-PLEX Aβ 
Peptide Panel 1 (4G8) Kit (Meso Scale Discovery, Gaithersburg, MD, USA). FA-soluble 
total brain extracts were diluted up to 1:10 in buffer (Diluent 35, Meso Scale Discovery) 
before measurement. Data analysis used MSD® DISCOVERY WORKBENCH® software 
2.0. Internal reference samples were used as a control in every plate. 
Aβ  immunohistochemical analysis  
After freezing, fixed brains were cut into serial, 25 µm-thick coronal sections using a 
freezing-sliding microtome. The sections were collected in tissue cryoprotection solution 
(35% ethylene glycol, 25% glycerol in PBS) and stained immunohistochemically with a 
customized polyclonal anti-Aβ-antibody and the Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA) as previously described (Eisele et al. 2010). Sections were 
counterstained with Congo red for amyloid according to standard protocols. Representative 
images are shown in Figure 1 for the two different treatment groups. 
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Quantification of total Aβ  plaque load  
In mice inoculated with Aβ seeds Aβ plaque load was stereologically quantified in the 
neocortex of representative sections of an Aβ-immunostained set of every 12th systematically 
sampled, serial, coronal section. A microscope equipped with a motorized x–y–z stage 
coupled to a video-microscopy system and the Stereo Investigator software 
(MicroBrightField, Inc., Williston, VT, USA) was used as previously described (Bondolfi et 
al. 2002). The person who performed the analysis was blind to the treatment groups. The total 
Aβ load (percentage) was determined by calculating the areal fraction occupied by Aβ-
positive staining in two-dimensional sectors (20×/0.45 objective).  
For the rest of the mice the number of Aβ positive stainings was counted manually in 
representative sections of an Aβ-immunostained set of every 12th systematically sampled, 
serial, coronal section using a 10x objective (0.30 numerical aperture) and a Zeiss Axioskop 
2 microscope (Zeiss, Oberkochen, Germany). 
 
Statistical Analysis 
GraphPadPrism (version 6.0) was used for statistical analyses and graphics. Normal 
distribution was assessed using the Shapiro-Wilk test. Non-normal-distributed variables were 
logarithmic-transformed. In all cases statistical significance was set at P < 0.05. All values 
are expressed as means ± SEM. 
 
 
RESULTS 
 
Passive immunization targeting early exogenously applied Aβ seeds decreases cerebral 
β-amyloidosis 
We have previously reported that the Aβ specific antibody β1 mixed with an APP23 brain 
extract can effectively attenuate amyloid induction (Meyer-Luehmann et al. 2006). To 
investigate whether immunotherapy using the β1 antibody to remove Aβ seeds at early stages 
prevents the induction of cerebral β-amyloidosis we immunized young pre-depositing APP23 
mice with the β1 antibody after intrahippocampal inoculation with amyloid-laden brain 
extracts of aged APP23 animals. Once daily for the first five consecutive days starting three 
hours post Aβ seed inoculation mice were intraperitoneally injected with either the β1 or a 
control antibody (Figure 1 A). Four months later immunohistochemical analyses revealed 
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less induced Aβ deposition in APP23 host mice that were injected with the β1 antibody 
compared to control animals (Figure 1 B, C). Stereological quantification revealed a 
significant reduction by 77% (Figure 1 D) indicating that an early inactivation of Aβ seeds by 
anti-Aβ immunotherapy might be an effective paradigm to prevent amyloid formation. 
 
BACE inhibition combined with Aβ immunization target initial endogenous Aβ seeds in 
APP23 mice 
In order to translate our findings in immunized mice injected with exogenously applied Aβ 
seeds to targeting strategies of endogenous Aβ seeds we used young pre-depositing APP23 
mice. We first set out to define the pre-depositing phase of APP23 animals to narrow down 
the time of putative first Aβ seed generation. Brain Aβ levels of 1-8 month-old APP23 mice 
were measured with and without formic acid (FA) extraction to reveal the age when first FA-
soluble Aβ seeds become apparent. While the omission of FA did not reveal any difference in 
cerebral Aβ40,42 levels of 1-8 month-old APP23 mouse brain extracts, the FA-soluble 
fraction of the same samples showed a significant increase in brain Aβ concentration with 
age (Figure 2). After seven months of age first significant increases in FA soluble brain Aβ or 
Aβ seeds could be measured compared to younger animals.  
Based on those results we treated pre-depositing APP23 mice with the β1 antibody, a potent 
BACE inhibitor NB-360 (0,5 g inhibitor / kg food pellets; Novartis, Basel, Switzerland 
(Shimshek et al. 2016; Bacioglu et al. 2016; Neumann et al. 2015), or a combination of both 
for a short but defined time starting at six months of age before significant Aβ seeds became 
apparent (Figure 3 A). The β1 antibody was intraperitoneally injected once daily for the first 
five consecutive days in accordance to the previous study. The BACE inhibitor was applied 
in food pellets either for 45 days until preparation (group 3 and 4) or for 42 days until 
replacement by control pellets three days before preparation (group 5 and 6). Already 24 
hours after administration NB-360 is not detectable anymore in blood and brain and therefore 
soluble Aβ levels are in a physiological range again (Neumann et al. 2015). A control group 
of mice received a control antibody as well as control food pellets. After 45 days all the mice 
were prepared. Mice that received until preparation the BACE inhibitor alone or in 
combination with β1 showed significantly less brain Aβ40,42 levels compared to control 
littermates or mice only treated with β1 (Figure 3 B). Similar results were obtained in NB-
360-treated and NB-360 and β1-treated mice that were fed with control food pellets three 
days before preparation. The slight tendency towards less brain Aβ40,42 in mice that 
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received the BACE inhibitor until preparation compared to those animals whose food pellets 
were changed to control ones after 42 days can be explained by acutely decreased soluble Aβ 
levels due to the presence of NB-360. Soluble Aβ levels are expected to normalize after three 
days of NB-360 absence in the administered food pellets. Aβ immunohistochemistry revealed 
more than 75% less positive Aβ staining in NB-360-treated mice with β1 immunization 
(group 4 and 6) or without β1 treatment (group 5) in comparison to mice treated with only the 
β1 or a control antibody (Figure 3 C). Because of the small number of animals and one 
biological outlier the number of Aβ positive staining was only reduced by 60% in mice 
treated with β1 in addition to NB-360 for 45 days (group 3). Control and only β1-treated 
groups did not differ. Therefore a combinational treatment based on NB-360 application and 
β1 immunization seems to be the best strategy to prevent the development of first detectable 
Aβ seeds.  
  
Interference with initial Aβ seeds delays plaque deposition in APP23 mice 
To evaluate the long-term effect of our combination treatment we provided 6 month-old 
APP23 mice with the NB-360 pellets for 45 days and injected the β1 antibody once daily for 
the first five consecutive days (Figure 4 A). Afterwards the mice were incubated for another 
4.5 months without any treatment. Control littermates received control food pellets as well as 
a control antibody. Control mice sacrificed already after 10.5 months of age were used as a 
baseline group. In NB-360 and β1 treated animals brain Aβ40,42 was kept on baseline level 
(Figure 4 B). Furthermore the age-dependent increase in amyloid plaque formation was 
completely prevented after combination treatment at early stages of deposition (Figure 4 C).  
 
BACE inhibition combined with Aβ immunization target initial endogenous Aβ seeds in 
APP51 mice 
APP51 mice do not harbor the Swedish mutation which causes higher affinity of BACE1 for 
APP and therefore less potency of a BACE inhibitor (Citron 2002; Bodendorf et al. 2002; 
Vassar et al. 1999)  but express human wildtype APP. Hence, similar to our experiments in 
APP23 mice pre-depositing APP51 mice were treated with NB-360 containing food pellets 
for 42 days, the β1 antibody for the first five consecutive days, or a combination of both 
(Figure 5 A). To diminish the acute BACE inhibitor effect NB-360-containing food pellets 
were exchanged by control pellets three days before preparation. Control pellets and control 
antibody were applied to littermates. Biochemical analyzes revealed significantly reduced 
brain Aβ40,42 concentrations (Figure 5 B) as well as Aβ positive staining (Figure 5 C) in 
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groups of mice that received NB-360 either alone or in addition to the β1 antibody when 
compared to control mice. Immunization with the β1 antibody alone did not differ from 
control littermates. 
 
Interference with initial Aβ seeds delays plaque deposition in APP51 mice 
In order to establish whether our combination treatment in APP51 mice at the beginning of 
seed formation effects the further development of amyloid deposition we again fed mice the 
NB-360 pellets for 45 days and immunized the mice using the β1 antibody (Figure 6 A). 
However, in this experiment 2 mg β1 antibody were applied once weekly to increase the 
probability to target arising Aβ seeds rather than residual soluble Aβ. Control mice, fed with 
control food pellets and injected with a control antibody, were either sacrificed after 18 or 
16.5 months of age as baseline group. Aβ40,42 concentrations in the brains of 18 month-old 
control mice were elevated compared to 1.5 months younger animals. Early NB-360 and β1 
treatment completely blocked this age-dependent increase in brain Aβ (Figure 6 B). Similar 
results were obtained with regards to Aβ immunohistochemistry. Early combination 
treatment prevented the age-dependent increase in plaque formation (Figure 6 C).  
 
 
DISCUSSION 
 
To date estimated 40 million patients suffer from AD worldwide. So far treatments for AD 
induce relatively rapid but only temporary amelioration of the symptoms without slowing the 
decline of cognitive functions over years. Approved symptomatic drugs include acetyl 
cholinesterase inhibitors and a glutamate antagonist, memantine, and have become the 
standard of care for AD patients (Ising et al. 2015). However, disease-modifying compounds 
are highly needed in order to slow disease progression without major side effects. Recent 
therapeutic approaches for AD have been focused on anti-amyloid agents targeting Aβ as the 
key trigger of the disease. Genetics of the human disease including inherited missense 
mutations of APP (Hardy & Selkoe 2002) and presenilin 1 or 2 causing familial forms of AD 
(De Strooper et al. 1998), Aβ seed inoculation experiments in APP tg mice inducing cerebral 
β-amyloidosis (Meyer-Luehmann et al. 2006; Walker et al. 2002; Kane et al. 2000), and 
several fluid and neuroimaging biomarker studies (Villemagne et al. 2013; Bateman et al. 
2012; Buchhave et al. 2012; Jack et al. 2010) support the amyloid cascade hypothesis 
proposing a key role for Aβ dyshomeostasis in initiating AD (Selkoe & Hardy 2016; Hardy 
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& Selkoe 2002). Specific reasons for the failures of therapeutic agents targeting Aβ in recent 
clinical trials are mainly based on insufficient safety standards, relative imprecision of a 
clinical diagnosis of AD, and the mild to moderate clinical stage of AD patients (Selkoe 
2013). Recent biomarker analyses of a familial AD cohort suggest that Aβ42 levels in CSF 
begin to decline 25 years before the onset of the expected abnormalities on standard cognitive 
tests for dementia (Bateman et al. 2012). This is followed by the appearance of fibrillar 
amyloid deposits in the brain and increased CSF tau levels. Given that pathological 
alterations occur long before diagnosis of dementia, anti-amyloid approaches seem to be 
clinically feasible when applied before the onset of significant neurodegeneration. In this 
study we used the Aβ specific antibody β1 (Meyer-Luehmann et al. 2006; Pfeifer et al. 2002) 
to bind and clear exogenously applied Aβ seeds and therefore ameliorate the induction and 
propagation of Aβ aggregation in APP tg mice after several months. We then transferred this 
passive Aβ immunization approach to targeting strategies of early endogenous Aβ seeds and 
could not detect significant Aβ reductions in brain of young APP tg mice.  These results 
suggest that endogenous Aβ seeds are different from exogenously applied Aβ seeds. Reasons 
may be that the exogenously applied seeds end up in a cellular department more accessible to 
antibodies, or that initial endogenous seeds have different conformational features compared 
to the seeds extracted from an aged amyloid-laden brain. Support for the latter interpretation 
comes from recent findings that the most seeding active Aβ aggregates occur at early stages 
of the amyloid formation (Ye et al., under review). Another explanation for the 
ineffectiveness of the β1 antibody in targeting endogenous Aβ seeds might be that the ratio of 
Aβ seeds and soluble Aβ species is much higher in mice inoculated with APP tg brain 
material compared to young pre-depositing APP tg mice. Therefore the β1 antibody was 
combined with a BACE inhibitor, which is supposed to block the amyloidogenic pathway of 
APP processing and therefore lowers the production of soluble Aβ monomers. In two 
different APP tg mouse models we show that a short combinational treatment applied at a 
defined pre-depositing stage significantly decreased both Aβ seeds acutely and amyloid 
deposition even after discontinuation of the treatment for several months. Although APP 
harboring the Swedish mutation is known to increase BACE1 cleavage of APP (Citron 2002; 
Bodendorf et al. 2002; Vassar et al. 1999) and should therefore lower the potency of a drug 
targeting this enzyme our results revealed similar reductions in amyloid pathology 
independent of the presence of the Swedish mutation. While chronic BACE inhibition or Aβ 
immunotherapy can evoke adverse neurochemical effects our short therapeutic intervention 
seems to be a promising therapeutic approach in order to safely delay the onset of cerebral β-
	   87	  
amyloidosis. Thus, interference with the early phase of amyloid formation by targeting initial 
Aβ seeds might be an effective paradigm to prevent cerebral β-amyloidosis and eventually 
AD. The preventive effect of the combined anti-amyloid agents in mice expressing human 
APP harboring the Swedish double mutation as well as in human wildtype APP tg mice 
suggests the potential efficacy of the short and early treatment in not only familial AD 
patients but also sporadic AD cases.  
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FIGURES 
 
 
Figure 1: Short and early anti-Aβ immunization attenuates induced cerebral β-amyloidosis. 
Female APP23 mice (3–4 months of age; 3–6 mice per group) were intracerebrally injected 
with amyloid-laden brain extract of aged APP23 mice and intraperitoneally immunized once 
daily for five consecutive days starting three hours post inoculation. Aβ seed inoculated mice 
were either injected with 0.5 mg of the Aβ specific antibody Beta-1 (β1) or 0.5 mg of an 
IgG2a control antibody (IgG2a ctrl), respectively. Brains were analyzed 
immunohistochemically four months after intracerebral injection. (A) Schematic overview of 
experimental design. (B, C) Shown are representative sections of the dentate gyrus of the 
hippocampus for IgG2a ctrl (B) or β1-injected mice (C) (scale bar is 200 µm). (D) 
Stereological quantification of hippocampal Aβ immunostaining (Aβ load) exhibited 
significantly less induced Aβ deposition after β1 treatment compared to control mice (t-test t7 
= 6.207, ***P < 0.001). All data are represented as group means ± SEM.  
 
A  plaque load in seeded APP23 mice
1 2
0
5
10
15
20
To
ta
l A
 lo
ad
  (%
) ***
Treatment group
B
C
D
Age [months] 
1. IgG2a ctrl
5d
7.53.5
2. β1
Treatment
group
No
treatment
APP23
   β1
3 h post 
inoculationAPP23
Brain extract 
containing Aβ seeds
Inoculation
A
	   91	  
 
 
Figure 2: FA-soluble Aβ seeds increase in APP23 mice at 7 months of age. 1–8 month-old 
male APP23 mice  (6–7 mice per group) were analyzed regarding their brain Aβ40,42 levels 
with and without formic acid (FA) extraction. Two-way ANOVA revealed significant age x 
extraction interaction (F7, 45 = 14.1, P < 0.001). Notably, Tukey’s post hoc test revealed that 
non-FA extracted brain homogenates did not differ, but FA-extracted brain samples of seven 
and eight month-old mice showed significantly increased brain Aβ40,42 levels compared to 
younger animals (P < 0.001). All data are represented as group means ± SEM. 
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Figure 3: Passive immunization combined with BACE inhibition reduces brain Aβ levels and 
plaque deposition in APP23 mice. Six month-old male APP23 mice (6–8 mice per group) 
were either intraperitoneally injected with the Aβ specific antibody Beta-1 (β1) once daily for 
five consecutive days (group 2), fed with BACE inhibitor NB-360-containing pellets (BI) for 
45 (group 3) or 42 days (group 5), or received a combination of 45 day NB-360 and five days 
β1 (group 4) or 42 days NB-360 and five days β1 (group 6). Mice of group 5 and 6 were 
supplied with control food pellets three days before preparation. Control mice were injected 
with a control IgG2a antibody (IgG2a ctrl) and fed with control food pellets (Ctrl) (group 1). 
All mice were sacrificed at 7.5 months of age. (A) Schematic overview of experimental 
design. (B) Measurements of Aβ levels in brain exhibited a significant decrease in mice 
treated with only NB-360 or a combination of β1 and NB-360 independent of the duration of 
NB-360 administration compared to control or only β1-treated animals (ANOVA F5, 47 = 
51.36, P < 0.0001; Tukey’s post hoc test ***P < 0.001). (C) Quantification of cerebral Aβ 
immunostaining revealed a similar result (ANOVA F5, 43 = 12.36, P < 0.0001; Tukey’s post 
hoc test **P < 0.01, ***P < 0.001). All data are represented as group means ± SEM. 
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Figure 4: Targeting early Aβ seeds delays cerebral β-amyloidosis in APP23 mice. 6 month-
old male APP23 mice (6–8 mice per group) were intraperitoneally injected with the Aβ 
specific antibody Beta-1 (β1) once daily for five consecutive days and were additionally fed 
with BACE inhibitor NB-360-containing pellets (BI) for 45 days. Littermates were 
immunized with control IgG2a antibody (IgG2a ctrl) and fed with control food pellets (Ctrl). 
After 45 days until preparation standard food pellets were supplied. NB-360 and β1-treated 
animals as well as one control group was prepared after 12 months of age. Other control mice 
served as baseline group and were prepared with 10.5 months of age. (A) Schematic 
overview of experimental design. (B) Brain Aβ level measurements revealed an age-
dependent increase in 12 month-old compared to 10.5 month-old animals, which could be 
completely blocked by NB-360 and β1 treatment (ANOVA F2, 18 = 12.01, P < 0.001; Tukey’s 
post hoc test **P < 0.01, ***P < 0.001). (C) Immunohistochemistry confirmed those results. 
NB-360 and β1-treated animals showed similar amounts of Aβ positive staining in the brain 
than 1.5 months younger controls (ANOVA F2, 18 = 13.01, P < 0.001; Tukey’s post hoc test 
**P < 0.01, ***P < 0.001). All data are represented as group means ± SEM. 
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Figure 5: Passive immunization combined with BACE inhibition reduces brain Aβ levels and 
plaque deposition in APP51 mice. 12 month-old female APP51 mice (6–8 mice per group) 
were either intraperitoneally injected with the Aβ specific antibody Beta-1 (β1) once daily for 
five consecutive days, fed with BACE inhibitor NB-360-containing pellets (BI) for 42 days, 
or received a combination of both treatments. Control mice were injected with a control 
IgG2a antibody (IgG2a ctrl) and fed with control food pellets (Ctrl). All mice were sacrificed 
with 13.5 months of age and supplied with control food pellets three days before preparation. 
(A) Schematic overview of experimental design. (B) Measurements of Aβ levels in brain 
exhibited a significant decrease in mice treated with only NB-360 or a combination of the β1 
antibody and NB-360 compared to control animals (ANOVA F3, 25 = 13.15, P < 0.001; 
Tukey’s post hoc test *P < 0.05, ***P < 0.001). (D) Quantification of cerebral Aβ 
immunostaining revealed that control mice had 78% and 86% more positive Aβ staining than 
NB-360 or NB-360 and β1-treated animals, respectively (ANOVA F3, 25 = 11.64, P < 0.001; 
Tukey’s post hoc test **P < 0.01, ***P < 0.001). All data are represented as group means ± 
SEM. 
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Figure 6: Targeting early Aβ seeds delays cerebral β-amyloidosis in APP51 mice. 12 month-
old male APP51 mice (8–11 mice per group) were intraperitoneally injected with the Aβ 
specific antibody Beta-1 (β1) once weekly for five times and were additionally fed with 
BACE inhibitor NB-360-containing pellets (BI) for 45 days. Littermates were immunized 
with control IgG2a antibody (IgG2a ctrl) and fed with control food pellets (Ctrl). After 45 
days until preparation standard food pellets were supplied. NB-360 and β1-treated animals as 
well as one control group was prepared after 18 months of age. Other control mice served as 
baseline group and were prepared with 16.5 months of age. (A) Schematic overview of 
experimental design. (B) Brain Aβ level measurements revealed an age-dependent increase in 
18 month-old compared to 16.5 month-old animals, which could be completely blocked by 
NB-360 and β1 treatment (ANOVA F2, 25 = 9.468, P < 0.001; Tukey’s post hoc test **P < 
0.01). (C) Immunohistochemistry confirmed those results. NB-360 and β1-treated animals 
showed similar amounts of Aβ positive staining in the brain than 1.5 months younger 
controls (ANOVA F2, 25 = 12.70, P < 0.001; Tukey’s post hoc test **P < 0.01, ***P < 0.001). 
All data are represented as group means ± SEM. 
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4. Appendix 
4.1 Abbreviations 
A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease trial 
ABCA 7 ATP-binding cassette sub-family A member 7 
ACh Acetylcholine 
AD Alzheimer’s disease 
ADAD Autosomal-dominant AD 
ADAM A disintegrin and metalloprotease 
AICD APP intracellular domain 
ALS Amyotrophic lateral sclerosis 
Aph-1 Anterior pharynx-defective phenotype 1 
API Alzheimer’s Prevention Initiative 
APOE Apolipoprotein E 
APOE4 ε4-allele of the APOE 
APP β-amyloid precursor protein 
APP695, APP751, APP770 APP isoforms 695, 751, 770 amino acids in length 
APPSwedish K670M/N671L-mutated human APP 
Aβ Amyloid-β peptide 
Aβ40, Aβ42 Aβ ending at amino acid 40, 42 
Aη Amyloid-η peptide 
β1 Beta-1 antibody 
BACE1, BACE2 β-site APP cleaving enzyme 1, 2 
BBB Blood-brain-barrier 
BIN1 Bridging integrator protein 1 
BSE Bovine spongiform encephalopathy 
C-terminal Carboxyterminal 
CD33 Member of the sialic-acid-binding immunoglobulin-like lectins family 
CJD Creutzfeldt-Jakob disease 
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CNS Central nervous system 
CR1 Complement receptor 1 
CSF Cerebrospinal fluid 
CTF C-terminal fragment 
CTFα/C83 CTF generated by α-secretase cleavage of APP (83 amino acids in length) 
CTFβ/C99 CTF generated by β-secretase cleavage of APP (99 amino acids in length) 
CTFη CTF generated by η-secretase cleavage of APP (30 amino acids in length) 
CWD Chronic wasting disease 
DIAN Dominantly Inherited Alzheimer Network 
DIAN-TU DIAN Trials Unit 
dpi Days post inoculation 
DSM-V Diagnostic and Statistical Manual of Mental Disorders 
EDTA Ethylenediaminetetraacetic acid  
ELISA Enzyme-linked immunosorbent assay  
EOAD Early onset Alzheimer’s disease 
FA Formic acid 
FAD Familial Alzheimer’s disease 
FDA Food and Drug Administration 
FDG 18F-fluorodeoxyglucose 
FFI Fatal familial insomnia 
GSS Gerstmann-Sträussler-Scheinker disease 
GWAS Genome-wide association studies 
HIV Human immunodeficiency virus 
i.p. Intraperitoneal 
LOAD Late onset Alzheimer’s disease 
MAPT Microtubule associated protein tau 
MCI Mild cognitive impairment 
MRI Magnetic resonance imaging 
NCT Nicastrin 
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NFTs Neurofibrillary tangles 
NMDA N-methyl-D-aspartate 
NINCDS/ ADRDA 
National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s Disease and Related Disorders Association 
p3 Product of the APP processing 
PiB Pittsburgh compound B 
PBS Phosphate-buffered saline 
PD Parkinson’s disease 
Pen-2 Presenilin enhancer 2 
PET Positron emission tomography 
PICALM Phosphatidylinositol-binding clathrin assembly protein 
PK Proteinase K 
Prion Proteinaceous infectious particle 
PrP Prion protein 
PS1/2 Presenilin 1/2 
PSEN1, PSEN2 Gene encoding presenilin 1, 2 
p-tau Phosphorylated tau 
sAPP Soluble amyloid precursor protein 
sAPPα sAPP generated by α-secretase 
sAPPβ sAPP generated by β-secretase 
SEM Standard error of the mean 
SIMOA Single molecule array 
SORL1 Sortilin-related receptor 1 
tg Transgenic 
Thy1 Thymocyte differentiation antigen 1 
TOMM40 Translocase of outer mitochondrial membrane 40 homolog 
TREM2 Triggering receptor expressed on myeloid cells 2 
t-tau Total tau  
wt Wild type 
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